{"gene":"FOXO4","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":2001,"finding":"NMR solution structure of the DNA-binding domain (forkhead domain) of FOXO4 (AFX) was determined, revealing a three-helix bundle resting on a small antiparallel beta-sheet with two wing-like loops, structurally similar to HNF3-gamma and FREAC-11 despite low sequence identity.","method":"High-resolution NMR spectroscopy","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution NMR structure with functional domain context, reported in peer-reviewed journal","pmids":["11352721"],"is_preprint":false},{"year":2003,"finding":"Two PKB/Akt phosphorylation sites (Thr-28 and Ser-193) on FOXO4 create binding motifs for 14-3-3 proteins; doubly phosphorylated FOXO4 forms a 1:2 complex with 14-3-3ζ (KD <30 nM), and both phosphorylation sites are required for complete inhibition of FOXO4 binding to its target DNA (insulin response element).","method":"In vitro phosphorylation by PKB, analytical gel filtration, sedimentation equilibrium, electrophoretic mobility shift assay","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro binding with quantitative biophysics and mutagenesis, multiple orthogonal methods","pmids":["14690436"],"is_preprint":false},{"year":2003,"finding":"CBP acetyltransferase interacts with FOXO4 (AFX/FOXO4) via its CH1 region and acetylates it at lysine residues K186, K189, and K408, resulting in inhibition of FOXO4 transcriptional activity; arginine substitutions at these lysines enhance transcriptional activity.","method":"Co-immunoprecipitation, site-directed mutagenesis (K→R), luciferase reporter assay, TSA treatment","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis with functional reporter assay, single lab, multiple methods","pmids":["12964026"],"is_preprint":false},{"year":2003,"finding":"Nuclear FOXO4 expression down-regulates HIF-1α protein levels through a mechanism independent of prolyl hydroxylation and VHL-mediated ubiquitin-proteasome degradation, thereby suppressing hypoxia-responsive genes (VEGF, GLUT1, EPO).","method":"Ectopic FOXO4 expression, prolyl hydroxylase inhibition, HIF-1α proline mutants, reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal approaches (mutants, inhibitors, reporters) in single lab","pmids":["12761217"],"is_preprint":false},{"year":2004,"finding":"CBP acetyltransferase binds FOXO4 and acetylates it upon oxidative stress (H2O2), inhibiting FOXO4 transcriptional activity; the NAD-dependent deacetylase hSir2(SIRT1) binds and deacetylates FOXO4, counteracting CBP-mediated inhibition and prolonging FOXO-dependent stress gene transcription.","method":"Co-immunoprecipitation, acetylation assays, siRNA knockdown, luciferase reporter assay, overexpression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, enzymatic assay, functional reporter, replicated across multiple FOXO family members and independent of earlier CBP study","pmids":["15126506"],"is_preprint":false},{"year":2005,"finding":"FOXO4 represses smooth muscle cell (SMC) differentiation by directly interacting with and inhibiting myocardin, a transcriptional coactivator of smooth muscle genes; PI3K/Akt-mediated nuclear export of FOXO4 releases myocardin from inhibition, promoting SMC differentiation. siRNA knockdown of FOXO4 enhances myocardin activity and SMC differentiation.","method":"Co-immunoprecipitation, siRNA knockdown, reporter assays, dominant-negative and constitutively active constructs, immunofluorescence","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP, siRNA loss-of-function with defined phenotype, reporter assays, multiple orthogonal methods","pmids":["16054032"],"is_preprint":false},{"year":2005,"finding":"Phosphorylation of FOXO4 at Thr-32 and Ser-197 (but not Ser-262) by PKB/Akt is required for cytoplasmic retention and transcriptional inactivation; mutations at Thr32 or Ser197 to Ala result in constitutive nuclear localization and 3–5-fold increased transcriptional activity.","method":"Site-directed mutagenesis, subcellular fractionation, immunoblotting with phosphosite-specific antibodies, transcriptional reporter assay","journal":"Journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis + fractionation + functional reporter, single lab but multiple orthogonal methods","pmids":["16272144"],"is_preprint":false},{"year":2005,"finding":"14-3-3 protein binding to phosphorylated FOXO4 NLS significantly changes the environment around the NLS and reduces its flexibility, as shown by site-directed AEDANS labeling and fluorescence spectroscopy; phosphorylation alone or DNA binding have only minor effects on NLS structure.","method":"Site-directed fluorescent labeling (AEDANS), steady-state and time-resolved fluorescence spectroscopy, in vitro kinase assay","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — fluorescence-based structural analysis with controls, single lab","pmids":["16114898"],"is_preprint":false},{"year":2005,"finding":"RANKL signaling through RANK Motif 1 (369PFQEP373) promotes osteoclast survival by activating Akt/PKB, which specifically phosphorylates FOXO4 (AFX) among multiple potential downstream targets, identifying FOXO4 as a key downstream effector of RANK-Akt signaling in osteoclast survival.","method":"RANK cytoplasmic motif mutagenesis, immunoblotting for phospho-FOXO4, osteoclast survival assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic domain mutagenesis combined with biochemical phosphorylation readout, single lab","pmids":["16260781"],"is_preprint":false},{"year":2006,"finding":"FOXO4 undergoes monoubiquitination in response to oxidative stress, which promotes its nuclear relocalization and increases transcriptional activity. The deubiquitinase USP7/HAUSP interacts with and deubiquitinates FOXO4 under oxidative stress conditions, negatively regulating FOXO4 transcriptional activity toward endogenous promoters without affecting protein half-life.","method":"Co-immunoprecipitation, in vivo ubiquitination assay, siRNA knockdown, subcellular fractionation, reporter assays","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, multiple orthogonal methods (fractionation, ubiquitination assay, reporter), single lab with rigorous controls","pmids":["16964248"],"is_preprint":false},{"year":2007,"finding":"FoxO4 activates transcription of the MMP9 gene in response to TNF-α signaling in vascular smooth muscle cells, requiring both the N-terminal Sp1-interactive domain and the C-terminal transactivation domain of FoxO4; FoxO4 knockdown (siRNA) or knockout reduces SMC migration in vitro and neointimal formation and MMP9 expression in vivo.","method":"siRNA knockdown, gene knockout, reporter assays (MMP9 promoter-luciferase), in vitro migration assay, in vivo vascular injury model","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO plus in vitro siRNA with defined mechanistic readouts and domain-mapping","pmids":["17242183"],"is_preprint":false},{"year":2007,"finding":"Both the N-terminal loop (upstream of helix H1) and wing W2 of the FOXO4 forkhead domain are required for stable DNA binding; deletion of either region partially reduces DNA binding, while simultaneous deletion of both significantly inhibits it. PKB-mediated phosphorylation of wing W2 significantly inhibits DNA binding only in the absence of the N-terminal loop; 14-3-3 binding efficiently reduces DNA binding regardless of N-terminal loop status.","method":"FRET time-resolved fluorescence spectroscopy, molecular dynamics simulations, in vitro DNA binding assays, in vitro PKB phosphorylation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — FRET structural analysis combined with mutagenesis and molecular dynamics, single lab","pmids":["17244620"],"is_preprint":false},{"year":2007,"finding":"AGE/RAGE signaling in podocytes causes Akt dephosphorylation and FOXO4 transcriptional activation, leading to upregulation of the pro-apoptotic protein Bim; siRNA-mediated knockdown of FOXO4 abolishes AGE-BSA-induced podocyte apoptosis.","method":"siRNA knockdown, immunoblotting, apoptosis assays (flow cytometry), FOXO4 transcriptional activity readout","journal":"Kidney international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function (siRNA) with defined downstream target (Bim) and apoptosis phenotype, single lab","pmids":["17667983"],"is_preprint":false},{"year":2008,"finding":"Mdm2 acts as an E3 ubiquitin ligase for FOXO4, directly co-immunoprecipitating with FOXO4 and inducing its (multi)mono-ubiquitination in vitro and in vivo in an ATP-dependent manner; siRNA-mediated depletion of Mdm2 inhibits H2O2-induced FOXO4 mono-ubiquitination, and Mdm2-mediated ubiquitination regulates FOXO4 transcriptional activity.","method":"In vitro ubiquitination assay, co-immunoprecipitation, siRNA knockdown, in vivo ubiquitination assay, reporter assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstituted ubiquitination assay plus Co-IP and in vivo siRNA rescue, multiple orthogonal methods","pmids":["18665269"],"is_preprint":false},{"year":2008,"finding":"TNF-α increases nuclear FOXO4 protein and induces atrogin-1/MAFbx mRNA expression in C2C12 myotubes via a mechanism independent of AKT-Foxo1/3 signaling; two distinct siRNA sequences targeting Foxo4 reduce TNF-induced atrogin mRNA by ~33%.","method":"siRNA knockdown, immunoblotting for nuclear FOXO4, qPCR for atrogin mRNA, pharmacological AKT inhibition (wortmannin)","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two independent siRNAs with phenotypic readout, pathway pharmacology controls, single lab","pmids":["18701653"],"is_preprint":false},{"year":2009,"finding":"Reactive oxygen species induce formation of cysteine-thiol disulfide-dependent complexes between FoxO4 and p300/CBP acetyltransferase; modulation of FoxO4 biological activity by p300/CBP-mediated acetylation is fully dependent on formation of this redox-dependent complex, directly linking cellular redox state to FoxO4 activity.","method":"Biochemical crosslinking, thiol-reactive probes, co-immunoprecipitation, mutagenesis of cysteine residues, transcriptional reporter assays","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (redox crosslinking, Co-IP, cysteine mutagenesis, functional reporters) in single rigorous study","pmids":["19648934"],"is_preprint":false},{"year":2009,"finding":"14-3-3 protein physically contacts and masks the DNA-binding interface of FOXO4 upon binding; six inter-protein FRET distances reveal that the forkhead domain of FOXO4 is docked within the central channel of the 14-3-3 dimer, without causing dramatic conformational change of FOXO4.","method":"Time-resolved FRET fluorescence spectroscopy, site-specific AEDANS labeling, tryptophan fluorescence","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — FRET distance measurements with multiple labeled sites, structural model validated by multiple spectroscopic methods","pmids":["19416966"],"is_preprint":false},{"year":2009,"finding":"FoxO4 inhibits NF-κB transcriptional activity; Foxo4-null mice show increased NF-κB activity in vivo and increased susceptibility to colonic injury-induced colitis, with upregulation of chemokine CCL5 and increased intestinal permeability due to downregulation of tight junction proteins ZO-1 and claudin-1.","method":"Foxo4 genetic knockout, microarray, NF-κB reporter assays, flow cytometry for immune cell infiltration, Western blot for tight junction proteins","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic KO with multiple molecular and cellular mechanistic readouts","pmids":["19560465"],"is_preprint":false},{"year":2009,"finding":"EGF/PI3K/Akt signaling causes phosphorylation of FOXO4 and inhibition of ANXA8 transcription in cholangiocarcinoma cells; FOXO4 phosphorylation downstream of EGFR-PI3K-Akt leads to inhibition of ANXA8 gene transcription, promoting EMT and metastasis.","method":"PI3K/Akt inhibitor treatment, FOXO4 overexpression, ANXA8 reporter assays, in vitro invasion assay, in vivo metastasis assay","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with functional phenotypic readouts, single lab","pmids":["19376120"],"is_preprint":false},{"year":2010,"finding":"Crystal structure of human FOXO4 DNA-binding domain in complex with 13-bp DNA at 1.9 Å resolution reveals helix H3 docked into the major groove providing all base-specific contacts, while the N-terminus and wing W1 contact phosphate groups; the H2-H3 loop has a different conformation from other FOXO-DBD structures and participates in DNA binding.","method":"X-ray crystallography (1.9 Å resolution crystal structure)","journal":"Acta crystallographica. Section D, Biological crystallography","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structure with atomic detail of protein-DNA contacts","pmids":["21123876"],"is_preprint":false},{"year":2010,"finding":"Ku70 (but not Ku80) is necessary and sufficient for interaction with FOXO4, identified by tandem-affinity purification/mass spectrometry; Ku70 inhibits FOXO4-mediated p27kip1 transcription and cell cycle arrest by >40%, and sequesters FOXO4 in the nucleus. Low levels of oxidative stress (50 µM H2O2) increase the Ku70-FOXO4 interaction stoichiometry while higher levels cause dissociation.","method":"Tandem-affinity purification, mass spectrometry, biochemical co-immunoprecipitation, luciferase reporter assay, Ku70 RNAi, immunofluorescence, flow cytometry, Ku70-/- ES cell rescue","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — unbiased proteomics discovery plus multiple orthogonal validation methods (Co-IP, reporter, RNAi, KO rescue, imaging)","pmids":["20570964"],"is_preprint":false},{"year":2010,"finding":"PKG activation causes β-catenin to bind FOXO4 in colon cancer cells in a JNK-dependent manner, leading to increased nuclear FOXO4 content and expression of FOXO target genes (MnSOD, catalase); FOXO4-specific siRNA completely blocks PKG-mediated inhibition of TCF transcriptional activity.","method":"Co-immunoprecipitation, siRNA knockdown, nuclear fractionation, luciferase reporter assays, pharmacological inhibitors","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and siRNA rescue with multiple reporter readouts, single lab","pmids":["20348951"],"is_preprint":false},{"year":2010,"finding":"O-GlcNAcylation of FOXO4 is induced by H2O2 treatment through increased association of FOXO4 with OGT (the O-GlcNAc transferase); O-GlcNAcylation enhances FOXO4 transcriptional activity under acute oxidative stress.","method":"Co-immunoprecipitation, O-GlcNAc immunoblotting, transcriptional reporter assay","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for protein-enzyme interaction plus functional reporter, single lab","pmids":["19932102"],"is_preprint":false},{"year":2011,"finding":"Ataxin-3 (ATXN3) interacts with FOXO4 and activates FOXO4-dependent transcription of the SOD2 gene; upon oxidative stress, ATXN3 and FOXO4 co-translocate to the nucleus and co-bind the SOD2 promoter; mutant ATXN3 (as in SCA3) has reduced ability to activate FOXO4-mediated SOD2 expression and interferes with FOXO4 binding to the SOD2 promoter.","method":"Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), reporter assays, ATXN3 RNAi knockdown, immunofluorescence","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP, ChIP, RNAi loss-of-function and gain-of-function with mechanistic promoter binding readout","pmids":["21536589"],"is_preprint":false},{"year":2011,"finding":"AGE-BSA treatment increases FOXO4 acetylation in podocytes; acetylation of FOXO4 (regulated by SIRT1, which is downregulated by AGE-BSA) is required for FOXO4 binding to the Bcl2l11 (Bim) promoter and transcriptional upregulation of Bim leading to podocyte apoptosis; SIRT1 overexpression prevents AGE-induced podocyte apoptosis.","method":"Chromatin immunoprecipitation (ChIP), FOXO4 acetylation immunoprecipitation, SIRT1 overexpression, siRNA, in vivo db/db mouse model","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP for direct promoter binding, acetylation biochemistry, in vitro and in vivo validation, multiple orthogonal methods","pmids":["21858169"],"is_preprint":false},{"year":2011,"finding":"FoxO4 inactivation downstream of the AMPK-mTORC1-S6K1-IRS-1-Akt2 pathway mediates adiponectin-induced vascular smooth muscle cell differentiation; adiponectin activates AMPKα2, which inhibits mTORC1/S6K1, stabilizing IRS-1 and driving Akt2-mediated FoxO4 phosphorylation and nuclear exclusion to allow contractile gene expression.","method":"siRNA knockdown of pathway components, overexpression, pharmacological inhibitors, VSMC differentiation assays","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological epistasis with defined phenotypic readout, single lab","pmids":["21454807"],"is_preprint":false},{"year":2012,"finding":"Foxk1 physically interacts with Foxo4 and represses Foxo4 transcriptional activity, thereby promoting muscle progenitor cell proliferation; Foxk1 knockdown causes cell cycle arrest and increased Foxo4 target gene expression, while Foxk1 overexpression retards muscle differentiation.","method":"Co-immunoprecipitation, reporter assays, siRNA knockdown, overexpression in C2C12 cells","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus loss/gain-of-function with functional cell cycle readout, single lab","pmids":["22956541"],"is_preprint":false},{"year":2015,"finding":"FoxO4 activates Arg1 (arginase 1) transcription by binding to a FoxO-binding site in the Arg1 promoter in endothelial cells; in FoxO4 endothelial-specific knockout mice, post-MI cardiac function is improved and neutrophil accumulation is reduced; FoxO4 acts upstream of Arg1 to suppress nitric oxide and promote neutrophil infiltration.","method":"Conditional endothelial/cardiomyocyte-specific knockout mice, luciferase reporter assay with Arg1 promoter, ChIP, siRNA, nitric oxide measurement, cardiac functional analysis (echocardiography)","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific in vivo KO, direct promoter binding (reporter + ChIP), multiple phenotypic readouts","pmids":["26438688"],"is_preprint":false},{"year":2017,"finding":"XBP1 unspliced form (XBP1u) directly associates with the N-terminus of FoxO4 in the cytoplasm, preventing FoxO4 nuclear translocation; blocking the XBP1u-FoxO4 interaction promotes nuclear FoxO4 translocation, represses smooth muscle cell marker genes, and stimulates aortic aneurysm formation in vivo, defining a XBP1u-FoxO4-myocardin axis in VSMC homeostasis.","method":"Co-immunoprecipitation, conditional SMC-specific XBP1 knockout mice, in vivo aneurysm models, immunofluorescence for nuclear FoxO4","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct protein interaction by Co-IP plus in vivo genetic model with functional consequence, multiple readouts","pmids":["29089350"],"is_preprint":false},{"year":2018,"finding":"WNK1 kinase positively regulates skeletal muscle cell hypertrophy by modulating FOXO4 nuclear localization; WNK1 silencing increases FOXO4 nuclear accumulation and induces atrogene (MAFbx and MuRF1) transcription and myotube atrophy, which is completely reversed by co-silencing of FOXO4.","method":"siRNA knockdown (WNK1, SPAK/OSR1, FOXO4), immunofluorescence for FOXO4 nuclear localization, qPCR for atrogenes, myotube diameter measurement","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis by double siRNA knockdown with defined phenotypic and molecular readouts, single lab","pmids":["29904119"],"is_preprint":false},{"year":2019,"finding":"Fhl2 interacts with Foxk1 and, in a dose-dependent fashion, promotes Foxk1-mediated transcriptional repression of Foxo4 activity, contributing to regulation of myogenic progenitor cell activity; Fhl2 knockdown results in cell cycle arrest.","method":"Yeast two-hybrid screen, transcriptional reporter assay, siRNA knockdown, immunohistochemistry","journal":"Stem cells (Dayton, Ohio)","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — yeast two-hybrid plus reporter assay and knockdown, single lab","pmids":["20013826"],"is_preprint":false},{"year":2020,"finding":"COP1 E3 ubiquitin ligase directly interacts with FOXO4 through a VP motif on FOXO4 and promotes its ubiquitin-mediated proteasomal degradation in response to EGF signaling; CSN6 enhances COP1 E3 ligase activity toward FOXO4. FOXO4 directly binds and suppresses promoters of serine-glycine-one-carbon (SGOC) pathway genes.","method":"Co-immunoprecipitation, ubiquitination assays, promoter-reporter and ChIP assays, CSN6 siRNA, metabolomics","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination assay, promoter binding, single lab with multiple methods","pmids":["33101846"],"is_preprint":false},{"year":2021,"finding":"The FOXO4 C-terminal disordered transactivation domain (TAD) binds β-catenin through two defined interaction sites, regulated by combined PKB/AKT- and CK1-mediated phosphorylation; β-catenin binding competes with an autoinhibitory intramolecular interaction between the FOXO4 TAD and its own forkhead DNA-binding domain, enhancing FOXO4 transcriptional activity. ICAT (β-catenin inhibitor) can bind β-catenin simultaneously with FOXO4.","method":"NMR spectroscopy, biochemical binding assays, phosphorylation mutagenesis, reporter assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR structural analysis combined with mutagenesis and functional reporter assays, multiple orthogonal methods","pmids":["34320339"],"is_preprint":false},{"year":2021,"finding":"FOXO4 TAD and the forkhead DNA-binding domain (FHD) form an intramolecular complex via hydrophobic interactions; TAD and DNA share the same FHD surface for binding, and the FHD-TAD complex selectively shows slow exchange with target DNA and fast exchange with non-target DNA, enabling selective target sequence recognition.","method":"Solution NMR spectroscopy, DNA binding assays","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — atomic-resolution NMR of intramolecular complex with functional DNA-binding kinetics, single lab","pmids":["33450250"],"is_preprint":false},{"year":2021,"finding":"FOXO4 directly binds the LDHA (lactate dehydrogenase A) promoter and inactivates its transcriptional activity in a dose-dependent manner; FOXO4 expression is itself transcriptionally repressed by HIF-1α under hypoxia, placing FOXO4 downstream of HIF-1α in the regulation of glycolysis.","method":"ChIP, promoter-reporter luciferase assay, FOXO4 overexpression/silencing, metabolic flux assays","journal":"Clinical and translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay for direct promoter binding, overexpression/KD with functional metabolic readout, single lab","pmids":["33463054"],"is_preprint":false},{"year":2021,"finding":"Fasting in humans activates FOXO4 in CD4+ T cells, and FOXO4 transcriptionally upregulates FKBP5 (FK506-binding protein 5); genetic gain- or loss-of-function of FOXO4 and FKBP5 modulates TH1 and TH17 cytokine production; FOXO4/FKBP5 axis downregulates mTORC1 signaling and suppresses STAT1/3 activation.","method":"RNA sequencing, flow cytometry, gain-of-function and loss-of-function genetic approaches, FOXO4 ChIP analysis (bioinformatics), cytokine measurement","journal":"Nature metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic gain/loss-of-function with defined cytokine phenotype, transcriptomic target identification, human subject data","pmids":["33723462"],"is_preprint":false},{"year":2021,"finding":"FOXO4 negatively regulates transcription of USP10; FoxO4 overexpression reduces USP10 levels and blocks Hippo/YAP signaling, aggravating apoptosis and oxidative stress in hypoxia/reoxygenation-treated cardiomyocytes.","method":"Dual luciferase reporter assay, ChIP, siRNA/overexpression, western blot for YAP pathway proteins, TUNEL and ROS assays","journal":"Journal of bioenergetics and biomembranes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay for direct promoter binding with functional phenotypic readout, single lab","pmids":["34251583"],"is_preprint":false},{"year":2021,"finding":"FOXO4 directly binds the ENPP2 promoter (transcription factor binding validated by dual-luciferase and ChIP assays) and inhibits ENPP2 expression; FoxO4 overexpression partially reverses ENPP2-mediated protection of cardiomyocytes against doxorubicin-induced ferroptosis.","method":"Dual-luciferase reporter assay, ChIP, overexpression, ferroptosis/oxidative stress assays","journal":"Molecular medicine reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter for direct promoter binding with functional rescue readout, single lab","pmids":["34296293"],"is_preprint":false},{"year":2021,"finding":"FOXO4 transcriptionally activates SOX9 by binding to its promoter (validated by ChIP and dual-luciferase reporter assay); Sirt1-mediated deacetylation of FOXO4 promotes SOX9 expression and stabilizes chondrocyte ECM. FOXO4 acetylation is increased by IL-1β, and FOXO4 knockdown abolishes Sirt1-induced SOX9 expression.","method":"ChIP, dual-luciferase reporter assay, FOXO4 siRNA knockdown, Sirt1 overexpression, Western blot for FOXO4 acetylation","journal":"European review for medical and pharmacological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay for promoter binding with siRNA epistasis, single lab","pmids":["33577016"],"is_preprint":false},{"year":2022,"finding":"FOXO4 interacts with both the transactivation domain (TAD) and cysteine-rich domain (CRD) of p53, as determined by NMR, chemical cross-linking, and analytical ultracentrifugation; p53 TAD interaction with the FOXO4 forkhead domain is essential for overall complex stability; complex formation blocks p53 binding to DNA but does not affect FOXO4's own DNA-binding properties.","method":"NMR spectroscopy, chemical cross-linking, analytical ultracentrifugation, in vitro DNA binding assays","journal":"Protein science","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple biophysical methods (NMR, AUC, crosslinking) with functional DNA binding assays in single rigorous study","pmids":["35481640"],"is_preprint":false},{"year":2022,"finding":"FoxO4 transcriptionally represses NFAT2 by binding to the NFAT2 promoter in human coronary artery endothelial cells (validated by ChIP and luciferase assay); Foxo4 knockout increases vasculitis in a mouse KD model, and NFAT2 inhibition reverses this effect, defining a FOXO4/NFAT2 axis in vascular inflammation.","method":"ChIP, luciferase reporter assay, Foxo4 knockout mice, NFAT2 overexpression/knockdown, in vivo KD vasculitis model","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter with in vivo KO epistasis, single lab","pmids":["36700213"],"is_preprint":false},{"year":2022,"finding":"FoxO4 directly binds and transcriptionally represses the Dkk3 (Dickkopf-3) gene (identified by genome-wide occupancy/ChIP-seq and transcriptomics); DKK3 mediates FoxO4's suppression of IFN-γ production in Th1 cells by downregulating LEF1 expression; conditional FoxO4 deletion in CD4+ T cells enhances Th1 responses to bacterial infection.","method":"ChIP-seq (genome-wide occupancy), RNA-seq, conditional T cell-specific KO mice, recombinant DKK3 protein reconstitution, cytokine measurement","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq plus in vivo conditional KO with protein reconstitution epistasis, multiple orthogonal methods","pmids":["36106640"],"is_preprint":false},{"year":2022,"finding":"FOXO4 binds the CTRP3 promoter and inhibits CTRP3 transcription (validated by JASPAR prediction, ChIP, and luciferase reporter assay); FOXO4 upregulation in high-glucose conditions suppresses CTRP3 expression, modulating the Nrf2/NF-κB pathway in retinal pericytes.","method":"ChIP, dual-luciferase reporter assay, FOXO4 overexpression, bioinformatics (JASPAR)","journal":"Bioengineered","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter for direct promoter binding with functional overexpression readout, single lab","pmids":["35196182"],"is_preprint":false},{"year":2019,"finding":"KLF2 physically interacts with FOXO4 and cooperates with FOXO4 to induce transcription of p21, driving senescence of pancreatic cancer cells; knockdown of p21 or FOXO4 impairs KLF2-induced senescence.","method":"Co-immunoprecipitation, reporter assays, siRNA knockdown, senescence assays (SA-β-gal)","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, siRNA epistasis with defined senescence phenotype, single lab","pmids":["31866399"],"is_preprint":false},{"year":2021,"finding":"TET1 transcriptionally activates FOXO4 expression; FOXO4 directly interacts with β-catenin and sequesters it in the cytoplasm, inhibiting β-catenin-mediated transcription of Wnt target genes (including EpCAM); FOXO4 modulation reverses TET1 effects on EMT and cancer stem cell self-renewal.","method":"Co-immunoprecipitation, RNA-seq, overexpression and knockdown, β-catenin localization assay, reporter assays, liver metastasis in vivo model","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for direct interaction, RNA-seq target identification, in vivo rescue experiments, single lab","pmids":["35805009"],"is_preprint":false},{"year":2020,"finding":"FOXO4 binds the APC2 promoter and transcriptionally upregulates APC2 expression, leading to increased phosphorylated degradation of β-catenin and suppression of stemness genes; FOXO4 overexpression inhibits CRC cell migration and metastasis, which is reversed by APC2 knockdown.","method":"ChIP, overexpression, siRNA knockdown (APC2), in vivo metastasis assay, immunohistochemistry","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for direct promoter binding with siRNA epistasis and in vivo validation, single lab","pmids":["34631691"],"is_preprint":false}],"current_model":"FOXO4 is a forkhead transcription factor whose activity, subcellular localization, and protein interactions are regulated by multiple post-translational modifications—including PKB/Akt-mediated phosphorylation at Thr-28/Ser-197 (promoting 14-3-3 binding and cytoplasmic retention), CBP/p300-mediated acetylation (via redox-dependent disulfide complex formation, inhibiting activity), SIRT1-mediated deacetylation (restoring activity), Mdm2/COP1-mediated (poly)monoubiquitination (modulating nuclear localization and transcriptional activity), USP7/HAUSP-mediated deubiquitination, and O-GlcNAcylation (enhancing activity under stress)—and through direct protein-protein interactions with partners including 14-3-3, myocardin, β-catenin, p53, Ku70, Mdm2, ataxin-3, Foxk1, XBP1u, KLF2, and DKK3; FOXO4 directly binds promoters of target genes including p27, MMP9, Arg1, LDHA, SOD2, Bim, NFAT2, DKK3, APC2, ENPP2, USP10, SOX9, and CTRP3 to regulate cell cycle, apoptosis, differentiation, inflammation, oxidative stress response, glycolysis, and senescence."},"narrative":{"mechanistic_narrative":"FOXO4 is a forkhead transcription factor that integrates growth-factor and redox signaling to control cell cycle arrest, apoptosis, oxidative-stress responses, differentiation, and inflammation through a forkhead DNA-binding domain that docks helix H3 into the DNA major groove [PMID:11352721, PMID:21123876]. Its activity is gated chiefly by PI3K/Akt: phosphorylation at Thr-28/Thr-32 and Ser-193/Ser-197 creates 14-3-3 binding motifs, and the 14-3-3 dimer masks the DNA-binding interface to drive cytoplasmic retention and transcriptional inactivation, whereas phosphosite mutants are constitutively nuclear and hyperactive [PMID:14690436, PMID:16272144, PMID:19416966]. A second regulatory layer is redox-coupled and reversible: oxidative stress promotes cysteine-disulfide complex formation with CBP/p300, which acetylates FOXO4 to inhibit it, while SIRT1 deacetylates FOXO4 to restore stress-gene transcription, and concurrent monoubiquitination (by Mdm2) and O-GlcNAcylation (via OGT) drive FOXO4 into the nucleus and enhance activity, with USP7/HAUSP reversing the ubiquitin signal and COP1 instead targeting FOXO4 for proteasomal degradation [PMID:15126506, PMID:16964248, PMID:18665269, PMID:19648934, PMID:19932102, PMID:33101846]. FOXO4 transcriptional output is further tuned by an autoinhibitory intramolecular contact between its disordered C-terminal transactivation domain and the forkhead domain, which β-catenin binding relieves to boost activity and enable selective target recognition [PMID:34320339, PMID:33450250]. Through these mechanisms FOXO4 directly binds and activates targets including p27/p21, Bim, SOD2, and Arg1, and represses targets including LDHA, NFAT2, DKK3, and USP10 to enforce cell-cycle arrest, senescence, apoptosis, glycolytic control, and immune/vascular responses [PMID:20570964, PMID:21536589, PMID:21858169, PMID:26438688, PMID:33463054, PMID:34251583, PMID:36700213, PMID:36106640, PMID:31866399]. A prominent role is the repression of smooth muscle differentiation by direct binding and inhibition of the coactivator myocardin, an axis itself controlled by cytoplasmic sequestration via XBP1u [PMID:16054032, PMID:29089350].","teleology":[{"year":2001,"claim":"Established the structural basis for FOXO4 DNA recognition by defining its forkhead domain fold, the prerequisite for interpreting how modifications and partners control DNA binding.","evidence":"High-resolution NMR solution structure of the FOXO4 forkhead domain","pmids":["11352721"],"confidence":"High","gaps":["No DNA complex in this structure","Does not address full-length protein or regulatory regions"]},{"year":2003,"claim":"Defined how Akt signaling inactivates FOXO4 by showing that dual PKB phosphorylation builds 14-3-3 binding sites that block DNA binding, establishing the core off-switch.","evidence":"In vitro PKB phosphorylation, biophysical 14-3-3 binding (gel filtration, sedimentation), EMSA, mutagenesis","pmids":["14690436"],"confidence":"High","gaps":["Mechanism of cytoplasmic retention not yet resolved here","Performed in vitro with isolated domains"]},{"year":2003,"claim":"Identified acetylation as an inhibitory modification by mapping CBP-acetylated lysines whose mutation enhances activity, opening the acetylation arm of FOXO4 regulation.","evidence":"Co-IP, K→R mutagenesis, luciferase reporter, TSA treatment","pmids":["12964026"],"confidence":"Medium","gaps":["Single lab reporter-based readout","Physiological context of acetylation not addressed"]},{"year":2004,"claim":"Connected acetylation to redox state and showed it is reversible, establishing CBP/SIRT1 as an antagonistic acetylation-deacetylation switch that tunes FOXO4 stress-gene output.","evidence":"Co-IP, acetylation/deacetylation assays, siRNA, reporter assays under H2O2","pmids":["15126506"],"confidence":"High","gaps":["Direct deacetylated lysines not exhaustively mapped","Quantitative contribution to endogenous targets unclear"]},{"year":2005,"claim":"Refined the phosphorylation code by demonstrating that Thr-32/Ser-197 phosphorylation specifically governs nuclear exclusion and activity, distinguishing functional from non-functional sites.","evidence":"Site-directed mutagenesis, subcellular fractionation, phosphosite antibodies, reporter assay","pmids":["16272144"],"confidence":"High","gaps":["Ser-262 role left undefined","Kinetics of nuclear export not measured"]},{"year":2005,"claim":"Revealed a differentiation-control mechanism in which FOXO4 directly inhibits myocardin to repress smooth muscle gene programs, linking Akt-FOXO4 to vascular cell fate.","evidence":"Co-IP, siRNA, reporter assays, dominant-negative/CA constructs, immunofluorescence","pmids":["16054032"],"confidence":"High","gaps":["Interaction interface on myocardin not mapped","In vivo requirement not tested in this study"]},{"year":2005,"claim":"Provided spectroscopic evidence that 14-3-3 binding rigidifies the FOXO4 NLS, mechanistically explaining how phosphorylation-dependent 14-3-3 docking enforces cytoplasmic localization.","evidence":"Site-directed AEDANS labeling, fluorescence spectroscopy, in vitro kinase assay","pmids":["16114898"],"confidence":"Medium","gaps":["Structural inference rather than atomic model","Single lab"]},{"year":2006,"claim":"Established a ubiquitin arm of FOXO4 control by showing oxidative-stress monoubiquitination promotes nuclear localization and that USP7 reverses it, decoupling this regulation from protein turnover.","evidence":"Co-IP, in vivo ubiquitination assay, siRNA, fractionation, reporter assays","pmids":["16964248"],"confidence":"High","gaps":["Ubiquitinated lysines not mapped here","E3 ligase not identified in this study"]},{"year":2007,"claim":"Dissected the DNA-binding contributions of the N-terminal loop and wing W2 and showed how PKB phosphorylation and 14-3-3 differentially inhibit DNA binding, refining the structural off-switch.","evidence":"FRET spectroscopy, molecular dynamics, in vitro DNA binding, PKB phosphorylation","pmids":["17244620"],"confidence":"Medium","gaps":["In vitro fragment system","Endogenous relevance of loop deletions untested"]},{"year":2007,"claim":"Demonstrated FOXO4 functions as a transcriptional activator in a disease context by driving MMP9 in vascular smooth muscle, with in vivo loss-of-function reducing neointima.","evidence":"siRNA, knockout, MMP9 promoter reporter, migration assay, in vivo vascular injury","pmids":["17242183"],"confidence":"High","gaps":["Sp1 cooperation mechanism not fully resolved","Direct promoter occupancy details limited"]},{"year":2008,"claim":"Identified Mdm2 as the E3 ligase mediating oxidative-stress monoubiquitination of FOXO4, supplying the enzyme acting opposite USP7.","evidence":"In vitro and in vivo ubiquitination, Co-IP, siMdm2, reporter assay","pmids":["18665269"],"confidence":"High","gaps":["Lysine acceptor sites not mapped","Relationship to COP1-mediated degradation not addressed"]},{"year":2009,"claim":"Provided the molecular link between cellular redox state and acetylation by showing ROS-induced FOXO4–p300/CBP disulfide complexes are required for acetylation-dependent regulation.","evidence":"Redox crosslinking, thiol probes, Co-IP, cysteine mutagenesis, reporters","pmids":["19648934"],"confidence":"High","gaps":["Specific cysteine pairing in vivo not fully defined","Quantitative redox thresholds unclear"]},{"year":2009,"claim":"Resolved how 14-3-3 inhibits FOXO4 at the structural level, docking the forkhead domain into the 14-3-3 central channel to mask the DNA interface without gross conformational change.","evidence":"Time-resolved FRET, AEDANS labeling, tryptophan fluorescence","pmids":["19416966"],"confidence":"High","gaps":["Distance-based model rather than crystal structure","Full-length protein behavior inferred"]},{"year":2009,"claim":"Established FOXO4 as an in vivo suppressor of inflammation by showing Foxo4-null mice have elevated NF-κB activity and increased colitis susceptibility.","evidence":"Foxo4 knockout, microarray, NF-κB reporter, flow cytometry, Western blot","pmids":["19560465"],"confidence":"High","gaps":["Direct vs indirect NF-κB inhibition not separated","Tissue-specific contributions not isolated"]},{"year":2010,"claim":"Captured atomic-resolution FOXO4–DNA contacts, defining the base-specific recognition by helix H3 and phosphate contacts by the N-terminus and wing W1.","evidence":"1.9 Å X-ray crystal structure of FOXO4 DBD–DNA complex","pmids":["21123876"],"confidence":"High","gaps":["Isolated DBD only","Does not model regulatory modifications or partners"]},{"year":2010,"claim":"Identified Ku70 as a direct nuclear partner that sequesters FOXO4 and inhibits its p27-driven cell-cycle arrest, adding a redox-tunable protein-interaction control.","evidence":"TAP-MS, Co-IP, reporter, RNAi, Ku70-/- rescue, imaging, flow cytometry","pmids":["20570964"],"confidence":"High","gaps":["Interaction interface not mapped","Generality across cell types untested"]},{"year":2010,"claim":"Linked FOXO4 to Wnt/β-catenin signaling by showing PKG-induced β-catenin–FOXO4 binding redirects β-catenin to FOXO targets and away from TCF.","evidence":"Co-IP, siRNA, fractionation, reporters, pharmacological inhibitors","pmids":["20348951"],"confidence":"Medium","gaps":["Direct binding interface defined only later","JNK dependence mechanism unclear"]},{"year":2010,"claim":"Showed O-GlcNAcylation provides a stress-responsive activating modification, with OGT association enhancing FOXO4 activity under acute oxidative stress.","evidence":"Co-IP, O-GlcNAc immunoblotting, reporter assay","pmids":["19932102"],"confidence":"Medium","gaps":["Modified residues not mapped","Interplay with phosphorylation/acetylation not tested"]},{"year":2011,"claim":"Identified ataxin-3 as a coactivator that directs FOXO4 to the SOD2 promoter under oxidative stress, with disease-mutant ATXN3 impairing this protective program.","evidence":"Co-IP, ChIP, reporters, ATXN3 RNAi, immunofluorescence","pmids":["21536589"],"confidence":"High","gaps":["Direct vs scaffold role of ATXN3 unresolved","Other FOXO4 targets affected not surveyed"]},{"year":2011,"claim":"Demonstrated acetylation-dependent promoter selection by showing FOXO4 acetylation is required for Bim promoter binding, linking the SIRT1/CBP switch to apoptotic output in podocytes.","evidence":"ChIP, acetylation IP, SIRT1 overexpression, siRNA, db/db mouse model","pmids":["21858169"],"confidence":"High","gaps":["Acetyl-lysines driving promoter binding not pinpointed","Disease specificity of mechanism untested"]},{"year":2012,"claim":"Added Foxk1 as a repressive interactor controlling FOXO4 activity to balance progenitor proliferation versus differentiation.","evidence":"Co-IP, reporters, siRNA, overexpression in C2C12","pmids":["22956541"],"confidence":"Medium","gaps":["Interaction surface not mapped","In vivo relevance not tested"]},{"year":2017,"claim":"Revealed XBP1u as a cytoplasmic anchor of FOXO4 in the XBP1u–FOXO4–myocardin axis governing smooth muscle homeostasis and aneurysm protection.","evidence":"Co-IP, SMC-specific XBP1 KO mice, aneurysm models, immunofluorescence","pmids":["29089350"],"confidence":"High","gaps":["XBP1u binding determinants not atomically defined","Relationship to Akt/14-3-3 retention not integrated"]},{"year":2018,"claim":"Implicated WNK1 kinase as an upstream regulator of FOXO4 nuclear localization controlling atrogene-driven muscle atrophy, with FOXO4 silencing fully rescuing the phenotype.","evidence":"siRNA (WNK1, SPAK/OSR1, FOXO4), immunofluorescence, qPCR, myotube measurement","pmids":["29904119"],"confidence":"Medium","gaps":["Whether WNK1 acts directly on FOXO4 unproven","Phosphosite link not established"]},{"year":2019,"claim":"Showed FOXO4 cooperates with KLF2 to induce p21 and drive senescence, defining a partner-dependent senescence program.","evidence":"Co-IP, reporters, siRNA, SA-β-gal senescence assays","pmids":["31866399"],"confidence":"Medium","gaps":["Direct co-occupancy of p21 promoter not shown","Single cancer model"]},{"year":2019,"claim":"Extended the Foxk1 repression axis by identifying Fhl2 as a cofactor enhancing Foxk1-mediated repression of FOXO4 activity in myogenic progenitors.","evidence":"Yeast two-hybrid, reporter assay, siRNA, immunohistochemistry","pmids":["20013826"],"confidence":"Medium","gaps":["Y2H interaction not reciprocally validated in cells for FOXO4","Indirect effect on FOXO4"]},{"year":2020,"claim":"Identified COP1 as an E3 ligase that degrades FOXO4 via a VP motif under EGF signaling, distinguishing a proteolytic ubiquitin pathway from the non-degradative Mdm2 route.","evidence":"Co-IP, ubiquitination assays, ChIP/reporter, CSN6 siRNA, metabolomics","pmids":["33101846"],"confidence":"Medium","gaps":["Interplay with USP7/Mdm2 signaling not reconciled","Single lab"]},{"year":2020,"claim":"Demonstrated tumor-suppressive transcriptional output by showing FOXO4 activates APC2 to promote β-catenin degradation and suppress colorectal metastasis.","evidence":"ChIP, overexpression, APC2 siRNA, in vivo metastasis, IHC","pmids":["34631691"],"confidence":"Medium","gaps":["Direct promoter element not finely mapped","Single tumor type"]},{"year":2021,"claim":"Resolved the molecular basis of β-catenin–FOXO4 regulation, showing β-catenin binds the disordered TAD and relieves an autoinhibitory TAD–forkhead contact to enhance activity.","evidence":"NMR, biochemical binding, phosphomutagenesis, reporters","pmids":["34320339"],"confidence":"High","gaps":["Cellular stoichiometry of competition unknown","Phospho-regulation kinetics in vivo untested"]},{"year":2021,"claim":"Defined the autoinhibitory intramolecular TAD–FHD complex as a mechanism for selective target-DNA recognition through differential exchange kinetics.","evidence":"Solution NMR, DNA binding assays","pmids":["33450250"],"confidence":"High","gaps":["In-cell occurrence of the intramolecular state not directly observed","Effect of modifications on the equilibrium not fully mapped"]},{"year":2021,"claim":"Placed FOXO4 in glycolytic control downstream of HIF-1α, showing it directly represses LDHA while being itself repressed by HIF-1α under hypoxia.","evidence":"ChIP, reporter, overexpression/silencing, metabolic flux","pmids":["33463054"],"confidence":"Medium","gaps":["Single cancer context","Quantitative contribution to flux modest"]},{"year":2021,"claim":"Expanded FOXO4 repressive targets in cardiac stress by showing it suppresses USP10 and ENPP2 to modulate Hippo/YAP signaling, apoptosis, and ferroptosis.","evidence":"ChIP, dual-luciferase, siRNA/overexpression, TUNEL/ROS/ferroptosis assays","pmids":["34251583","34296293"],"confidence":"Medium","gaps":["Single-lab reporter-based mechanisms","Direct vs indirect ferroptosis effects unclear"]},{"year":2021,"claim":"Linked FOXO4 to SIRT1-dependent chondrocyte maintenance, showing deacetylated FOXO4 activates SOX9 to stabilize ECM.","evidence":"ChIP, dual-luciferase, FOXO4 siRNA, Sirt1 overexpression, acetylation Western","pmids":["33577016"],"confidence":"Medium","gaps":["Acetyl-residues controlling SOX9 binding not mapped","Single tissue model"]},{"year":2021,"claim":"Established a metabolic-immune role in which fasting-activated FOXO4 upregulates FKBP5 to dampen mTORC1/STAT signaling and modulate TH1/TH17 cytokines.","evidence":"RNA-seq, flow cytometry, FOXO4/FKBP5 gain/loss, ChIP bioinformatics, human data","pmids":["33723462"],"confidence":"Medium","gaps":["Direct FKBP5 promoter binding only bioinformatically inferred","Human genetics correlative"]},{"year":2022,"claim":"Defined how FOXO4 inhibits p53 by binding its TAD and CRD to block p53–DNA binding while leaving FOXO4's own DNA binding intact, revealing reciprocal transcription-factor cross-inhibition.","evidence":"NMR, chemical crosslinking, analytical ultracentrifugation, in vitro DNA binding","pmids":["35481640"],"confidence":"High","gaps":["Cellular consequences of p53 inhibition not assayed here","Regulation of the interaction unknown"]},{"year":2022,"claim":"Demonstrated FOXO4's vascular-immune role by repressing NFAT2 to restrain vasculitis, validated by in vivo KO epistasis.","evidence":"ChIP, luciferase, Foxo4 KO mice, NFAT2 manipulation, KD vasculitis model","pmids":["36700213"],"confidence":"Medium","gaps":["Promoter element not finely resolved","Single disease model"]},{"year":2022,"claim":"Provided genome-wide FOXO4 occupancy showing direct repression of Dkk3 to limit Th1 IFN-γ responses, integrating FOXO4 into T-cell immunity.","evidence":"ChIP-seq, RNA-seq, T-cell-specific conditional KO, DKK3 reconstitution, cytokines","pmids":["36106640"],"confidence":"High","gaps":["Full target landscape not analyzed beyond DKK3","Upstream activating signal in T cells not defined"]},{"year":2022,"claim":"Showed FOXO4 represses CTRP3 under hyperglycemia, modulating Nrf2/NF-κB signaling in retinal pericytes.","evidence":"ChIP, dual-luciferase, FOXO4 overexpression, JASPAR prediction","pmids":["35196182"],"confidence":"Medium","gaps":["Single cell type","Functional consequence largely correlative"]},{"year":null,"claim":"How the multiple, partly antagonistic modification arms (phosphorylation/14-3-3, acetylation, mono- vs degradative ubiquitination, O-GlcNAcylation) and the autoinhibitory TAD–FHD equilibrium are integrated to set FOXO4 target selectivity and activate or repress specific genes in a given cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified quantitative model of modification cross-talk","Determinants of activator vs repressor mode at individual promoters unknown","In-cell relevance of the intramolecular autoinhibited state not directly demonstrated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[5,10,17,23,27,34,40,41,45]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,19,33]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,39]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6,9,14,20,29]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,6,16,28,44]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,6,8,16,21,25]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[5,10,23,27,41]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[4,9,15,22,23]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[17,35,40,41]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[20,43]}],"complexes":[],"partners":["YWHAZ","CREBBP","SIRT1","MDM2","USP7","CTNNB1","TP53","XRCC6","ATXN3","XBP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P98177","full_name":"Forkhead box protein O4","aliases":["Fork head domain transcription factor AFX1"],"length_aa":505,"mass_kda":53.7,"function":"Transcription factor involved in the regulation of the insulin signaling pathway. Binds to insulin-response elements (IREs) and can activate transcription of IGFBP1. Down-regulates expression of HIF1A and suppresses hypoxia-induced transcriptional activation of HIF1A-modulated genes. Also involved in negative regulation of the cell cycle. Involved in increased proteasome activity in embryonic stem cells (ESCs) by activating expression of PSMD11 in ESCs, leading to enhanced assembly of the 26S proteasome, followed by higher proteasome activity","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P98177/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FOXO4","classification":"Not Classified","n_dependent_lines":12,"n_total_lines":1208,"dependency_fraction":0.009933774834437087},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FOXO4","total_profiled":1310},"omim":[{"mim_id":"621190","title":"MICRO RNA 617; MIR617","url":"https://www.omim.org/entry/621190"},{"mim_id":"611457","title":"FORKHEAD BOX O6; FOXO6","url":"https://www.omim.org/entry/611457"},{"mim_id":"607047","title":"ATAXIN 3; ATXN3","url":"https://www.omim.org/entry/607047"},{"mim_id":"606127","title":"MYOCARDIN; MYOCD","url":"https://www.omim.org/entry/606127"},{"mim_id":"604449","title":"PROTEASOME 26S SUBUNIT, NON-ATPase, 11; PSMD11","url":"https://www.omim.org/entry/604449"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear speckles","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"placenta","ntpm":109.6}],"url":"https://www.proteinatlas.org/search/FOXO4"},"hgnc":{"alias_symbol":["AFX1"],"prev_symbol":["MLLT7"]},"alphafold":{"accession":"P98177","domains":[{"cath_id":"1.10.10.10","chopping":"107-181","consensus_level":"high","plddt":91.4437,"start":107,"end":181}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P98177","model_url":"https://alphafold.ebi.ac.uk/files/AF-P98177-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P98177-F1-predicted_aligned_error_v6.png","plddt_mean":54.28},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FOXO4","jax_strain_url":"https://www.jax.org/strain/search?query=FOXO4"},"sequence":{"accession":"P98177","fasta_url":"https://rest.uniprot.org/uniprotkb/P98177.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P98177/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P98177"}},"corpus_meta":[{"pmid":"15126506","id":"PMC_15126506","title":"FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1).","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15126506","citation_count":455,"is_preprint":false},{"pmid":"16964248","id":"PMC_16964248","title":"FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP.","date":"2006","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16964248","citation_count":406,"is_preprint":false},{"pmid":"31004990","id":"PMC_31004990","title":"Inhibition of Brd4 alleviates renal ischemia/reperfusion injury-induced apoptosis and endoplasmic reticulum stress by blocking FoxO4-mediated oxidative stress.","date":"2019","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/31004990","citation_count":213,"is_preprint":false},{"pmid":"19648934","id":"PMC_19648934","title":"Redox-sensitive cysteines bridge p300/CBP-mediated acetylation and FoxO4 activity.","date":"2009","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/19648934","citation_count":170,"is_preprint":false},{"pmid":"16054032","id":"PMC_16054032","title":"Phenotypic modulation of smooth muscle cells through interaction of Foxo4 and myocardin.","date":"2005","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/16054032","citation_count":160,"is_preprint":false},{"pmid":"25007147","id":"PMC_25007147","title":"A novel CIC-FOXO4 gene fusion in undifferentiated small round cell sarcoma: a genetically distinct variant of Ewing-like sarcoma.","date":"2014","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25007147","citation_count":149,"is_preprint":false},{"pmid":"30249393","id":"PMC_30249393","title":"Hsa_circRNA_103809 regulated the cell proliferation and migration in colorectal cancer via miR-532-3p / FOXO4 axis.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30249393","citation_count":144,"is_preprint":false},{"pmid":"21934092","id":"PMC_21934092","title":"MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4.","date":"2011","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/21934092","citation_count":132,"is_preprint":false},{"pmid":"17667983","id":"PMC_17667983","title":"Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor.","date":"2007","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/17667983","citation_count":128,"is_preprint":false},{"pmid":"21858169","id":"PMC_21858169","title":"Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21858169","citation_count":117,"is_preprint":false},{"pmid":"19560465","id":"PMC_19560465","title":"FoxO4 inhibits NF-kappaB and protects mice against colonic injury and inflammation.","date":"2009","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19560465","citation_count":116,"is_preprint":false},{"pmid":"18665269","id":"PMC_18665269","title":"Mdm2 induces mono-ubiquitination of FOXO4.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18665269","citation_count":112,"is_preprint":false},{"pmid":"16114898","id":"PMC_16114898","title":"14-3-3 Protein interacts with nuclear localization sequence of forkhead transcription factor FoxO4.","date":"2005","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16114898","citation_count":106,"is_preprint":false},{"pmid":"12964026","id":"PMC_12964026","title":"Negative regulation of forkhead transcription factor AFX (Foxo4) by CBP-induced acetylation.","date":"2003","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12964026","citation_count":105,"is_preprint":false},{"pmid":"29089350","id":"PMC_29089350","title":"Unspliced XBP1 Confers VSMC Homeostasis and Prevents Aortic Aneurysm Formation via FoxO4 Interaction.","date":"2017","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/29089350","citation_count":103,"is_preprint":false},{"pmid":"29683489","id":"PMC_29683489","title":"Regulation of cellular senescence via the FOXO4-p53 axis.","date":"2018","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/29683489","citation_count":102,"is_preprint":false},{"pmid":"18701653","id":"PMC_18701653","title":"TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling.","date":"2008","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18701653","citation_count":94,"is_preprint":false},{"pmid":"17242183","id":"PMC_17242183","title":"FoxO4 regulates tumor necrosis factor alpha-directed smooth muscle cell migration by activating matrix metalloproteinase 9 gene transcription.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17242183","citation_count":93,"is_preprint":false},{"pmid":"14690436","id":"PMC_14690436","title":"Two 14-3-3 binding motifs are required for stable association of Forkhead transcription factor FOXO4 with 14-3-3 proteins and inhibition of DNA binding.","date":"2003","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14690436","citation_count":89,"is_preprint":false},{"pmid":"12761217","id":"PMC_12761217","title":"The forkhead transcription factor FOXO4 induces the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-independent mechanism.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12761217","citation_count":85,"is_preprint":false},{"pmid":"31959736","id":"PMC_31959736","title":"FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31959736","citation_count":84,"is_preprint":false},{"pmid":"21536589","id":"PMC_21536589","title":"FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21536589","citation_count":83,"is_preprint":false},{"pmid":"27976702","id":"PMC_27976702","title":"MiR-150 promotes cellular metastasis in non-small cell lung cancer by targeting FOXO4.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27976702","citation_count":81,"is_preprint":false},{"pmid":"31529218","id":"PMC_31529218","title":"Current perspective on the regulation of FOXO4 and its role in disease progression.","date":"2019","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/31529218","citation_count":75,"is_preprint":false},{"pmid":"26438688","id":"PMC_26438688","title":"FoxO4 promotes early inflammatory response upon myocardial infarction via endothelial Arg1.","date":"2015","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/26438688","citation_count":74,"is_preprint":false},{"pmid":"11352721","id":"PMC_11352721","title":"Solution structure of the DNA binding domain of the human forkhead transcription factor AFX (FOXO4).","date":"2001","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11352721","citation_count":72,"is_preprint":false},{"pmid":"15688030","id":"PMC_15688030","title":"Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15688030","citation_count":71,"is_preprint":false},{"pmid":"33463054","id":"PMC_33463054","title":"Hypoxia-induced FOXO4/LDHA axis modulates gastric cancer cell glycolysis and progression.","date":"2021","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33463054","citation_count":70,"is_preprint":false},{"pmid":"21454807","id":"PMC_21454807","title":"Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of rapamycin complex 1 and FoxO4.","date":"2011","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21454807","citation_count":66,"is_preprint":false},{"pmid":"17244620","id":"PMC_17244620","title":"Both the N-terminal loop and wing W2 of the forkhead domain of transcription factor Foxo4 are important for DNA binding.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17244620","citation_count":65,"is_preprint":false},{"pmid":"22956541","id":"PMC_22956541","title":"Foxk1 promotes cell proliferation and represses myogenic differentiation by regulating Foxo4 and Mef2.","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22956541","citation_count":64,"is_preprint":false},{"pmid":"23707940","id":"PMC_23707940","title":"miR-421 induces cell proliferation and apoptosis resistance in human nasopharyngeal carcinoma via downregulation of FOXO4.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23707940","citation_count":64,"is_preprint":false},{"pmid":"20348951","id":"PMC_20348951","title":"PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20348951","citation_count":63,"is_preprint":false},{"pmid":"26715362","id":"PMC_26715362","title":"microRNA-150 promotes cervical cancer cell growth and survival by targeting FOXO4.","date":"2015","source":"BMC molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26715362","citation_count":63,"is_preprint":false},{"pmid":"19416966","id":"PMC_19416966","title":"14-3-3 protein masks the DNA binding interface of forkhead transcription factor FOXO4.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19416966","citation_count":58,"is_preprint":false},{"pmid":"21123876","id":"PMC_21123876","title":"Structure of the human FOXO4-DBD-DNA complex at 1.9 Å resolution reveals new details of FOXO binding to the DNA.","date":"2010","source":"Acta crystallographica. Section D, Biological crystallography","url":"https://pubmed.ncbi.nlm.nih.gov/21123876","citation_count":57,"is_preprint":false},{"pmid":"33723462","id":"PMC_33723462","title":"Fasting-induced FOXO4 blunts human CD4+ T helper cell responsiveness.","date":"2021","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33723462","citation_count":56,"is_preprint":false},{"pmid":"19376120","id":"PMC_19376120","title":"ANXA8 down-regulation by EGF-FOXO4 signaling is involved in cell scattering and tumor metastasis of cholangiocarcinoma.","date":"2009","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19376120","citation_count":55,"is_preprint":false},{"pmid":"33634112","id":"PMC_33634112","title":"Exosomal miR-128-3p Promotes Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cells by Targeting FOXO4 via TGF-β/SMAD and JAK/STAT3 Signaling.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33634112","citation_count":53,"is_preprint":false},{"pmid":"24886657","id":"PMC_24886657","title":"The transcription factor FOXO4 is down-regulated and inhibits tumor proliferation and metastasis in gastric cancer.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24886657","citation_count":52,"is_preprint":false},{"pmid":"24983969","id":"PMC_24983969","title":"A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24983969","citation_count":48,"is_preprint":false},{"pmid":"28011648","id":"PMC_28011648","title":"Foxo4- and Stat3-dependent IL-10 production by progranulin in regulatory T cells restrains inflammatory arthritis.","date":"2016","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28011648","citation_count":43,"is_preprint":false},{"pmid":"30551491","id":"PMC_30551491","title":"Rosmarinic acid reduces the resistance of gastric carcinoma cells to 5-fluorouracil by downregulating FOXO4-targeting miR-6785-5p.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30551491","citation_count":43,"is_preprint":false},{"pmid":"23551888","id":"PMC_23551888","title":"FOXO4 is necessary for neural differentiation of human embryonic stem cells.","date":"2013","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/23551888","citation_count":42,"is_preprint":false},{"pmid":"35340217","id":"PMC_35340217","title":"Salvianolic Acid B Suppresses ER Stress-Induced NLRP3 Inflammasome and Pyroptosis via the AMPK/FoxO4 and Syndecan-4/Rac1 Signaling Pathways in Human Endothelial Progenitor Cells.","date":"2022","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/35340217","citation_count":41,"is_preprint":false},{"pmid":"30323875","id":"PMC_30323875","title":"FoxO4 promotes myocardial ischemia-reperfusion injury: the role of oxidative stress-induced apoptosis.","date":"2018","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/30323875","citation_count":40,"is_preprint":false},{"pmid":"33996787","id":"PMC_33996787","title":"Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes.","date":"2021","source":"Frontiers in bioengineering and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/33996787","citation_count":40,"is_preprint":false},{"pmid":"16272144","id":"PMC_16272144","title":"Regulation of intracellular localization and transcriptional activity of FOXO4 by protein kinase B through phosphorylation at the motif sites conserved among the FOXO family.","date":"2005","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16272144","citation_count":39,"is_preprint":false},{"pmid":"31030940","id":"PMC_31030940","title":"Adiponectin alleviates NLRP3-inflammasome-mediated pyroptosis of aortic endothelial cells by inhibiting FoxO4 in arteriosclerosis.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31030940","citation_count":36,"is_preprint":false},{"pmid":"20570964","id":"PMC_20570964","title":"The DNA damage repair protein Ku70 interacts with FOXO4 to coordinate a conserved cellular stress response.","date":"2010","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/20570964","citation_count":35,"is_preprint":false},{"pmid":"33103284","id":"PMC_33103284","title":"Resveratrol inhibits bile acid-induced gastric intestinal metaplasia via the PI3K/AKT/p-FoxO4 signalling pathway.","date":"2020","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/33103284","citation_count":35,"is_preprint":false},{"pmid":"34689087","id":"PMC_34689087","title":"Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells.","date":"2021","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/34689087","citation_count":35,"is_preprint":false},{"pmid":"35510614","id":"PMC_35510614","title":"FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway.","date":"2022","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35510614","citation_count":34,"is_preprint":false},{"pmid":"34320339","id":"PMC_34320339","title":"Multiple regulatory intrinsically disordered motifs control FOXO4 transcription factor binding and function.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34320339","citation_count":34,"is_preprint":false},{"pmid":"20013826","id":"PMC_20013826","title":"Fhl2 interacts with Foxk1 and corepresses Foxo4 activity in myogenic progenitors.","date":"2010","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/20013826","citation_count":33,"is_preprint":false},{"pmid":"25929834","id":"PMC_25929834","title":"FOXO1, FOXO3, AND FOXO4 are differently expressed during mouse oocyte maturation and preimplantation embryo development.","date":"2015","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/25929834","citation_count":32,"is_preprint":false},{"pmid":"33101846","id":"PMC_33101846","title":"EGF Relays Signals to COP1 and Facilitates FOXO4 Degradation to Promote Tumorigenesis.","date":"2020","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/33101846","citation_count":32,"is_preprint":false},{"pmid":"24935588","id":"PMC_24935588","title":"Low expression of the FoxO4 gene may contribute to the phenomenon of EMT in non-small cell lung cancer.","date":"2014","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/24935588","citation_count":31,"is_preprint":false},{"pmid":"21567078","id":"PMC_21567078","title":"Up-regulation of Foxo4 mediated by hepatitis B virus X protein confers resistance to oxidative stress-induced cell death.","date":"2011","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21567078","citation_count":31,"is_preprint":false},{"pmid":"34296293","id":"PMC_34296293","title":"Transcriptional activation of ENPP2 by FoxO4 protects cardiomyocytes from doxorubicin‑induced toxicity.","date":"2021","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/34296293","citation_count":30,"is_preprint":false},{"pmid":"21388494","id":"PMC_21388494","title":"Candidate gene study of FOXO1, FOXO4, and FOXO6 reveals no association with human longevity in Germans.","date":"2011","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/21388494","citation_count":28,"is_preprint":false},{"pmid":"26463624","id":"PMC_26463624","title":"Mir-664 promotes osteosarcoma cells proliferation via downregulating of FOXO4.","date":"2015","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/26463624","citation_count":27,"is_preprint":false},{"pmid":"35805009","id":"PMC_35805009","title":"Targeting Wnt/β-Catenin Signaling by TET1/FOXO4 Inhibits Metastatic Spreading and Self-Renewal of Cancer Stem Cells in Gastric Cancer.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35805009","citation_count":27,"is_preprint":false},{"pmid":"18687668","id":"PMC_18687668","title":"The forkhead transcription factor FOXO4 sensitizes cancer cells to doxorubicin-mediated cytotoxicity.","date":"2008","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/18687668","citation_count":27,"is_preprint":false},{"pmid":"25753202","id":"PMC_25753202","title":"The role of microRNA-1274a in the tumorigenesis of gastric cancer: accelerating cancer cell proliferation and migration via directly targeting FOXO4.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25753202","citation_count":27,"is_preprint":false},{"pmid":"19932102","id":"PMC_19932102","title":"O-GlcNAcylation enhances FOXO4 transcriptional regulation in response to stress.","date":"2010","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/19932102","citation_count":27,"is_preprint":false},{"pmid":"26780985","id":"PMC_26780985","title":"Overexpression of FOXO4 induces apoptosis of clear-cell renal carcinoma cells through downregulation of Bim.","date":"2016","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/26780985","citation_count":26,"is_preprint":false},{"pmid":"33238881","id":"PMC_33238881","title":"MiR-128-3p inhibits vascular smooth muscle cell proliferation and migration by repressing FOXO4/MMP9 signaling pathway.","date":"2020","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/33238881","citation_count":25,"is_preprint":false},{"pmid":"33798806","id":"PMC_33798806","title":"FOXO4 ameliorates alcohol-induced chronic liver injury via inhibiting NF-κB and modulating gut microbiota in C57BL/6J mice.","date":"2021","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33798806","citation_count":25,"is_preprint":false},{"pmid":"30972207","id":"PMC_30972207","title":"Long noncoding RNA LINC00341 promotes the vascular smooth muscle cells proliferation and migration via miR-214/FOXO4 feedback loop.","date":"2019","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/30972207","citation_count":25,"is_preprint":false},{"pmid":"16260781","id":"PMC_16260781","title":"Receptor activator of NF-kappaB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16260781","citation_count":25,"is_preprint":false},{"pmid":"20934750","id":"PMC_20934750","title":"Expression and localisation of FoxO3 and FoxO4 in human placenta and fetal membranes.","date":"2010","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/20934750","citation_count":24,"is_preprint":false},{"pmid":"9341872","id":"PMC_9341872","title":"AFX1 and p54nrb: fine mapping, genomic structure, and exclusion as candidate genes of X-linked dystonia parkinsonism.","date":"1997","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9341872","citation_count":22,"is_preprint":false},{"pmid":"20037138","id":"PMC_20037138","title":"Effects of FoxO4 overexpression on cholesterol biosynthesis, triacylglycerol accumulation, and glucose uptake.","date":"2009","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/20037138","citation_count":22,"is_preprint":false},{"pmid":"28769986","id":"PMC_28769986","title":"Curcumin Induces p53-Null Hepatoma Cell Line Hep3B Apoptosis through the AKT-PTEN-FOXO4 Pathway.","date":"2017","source":"Evidence-based complementary and alternative medicine : eCAM","url":"https://pubmed.ncbi.nlm.nih.gov/28769986","citation_count":21,"is_preprint":false},{"pmid":"21461610","id":"PMC_21461610","title":"Advanced glycation end-products induce heparanase expression in endothelial cells by the receptor for advanced glycation end products and through activation of the FOXO4 transcription factor.","date":"2011","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21461610","citation_count":21,"is_preprint":false},{"pmid":"37002972","id":"PMC_37002972","title":"Ponicidin inhibited gallbladder cancer proliferation and metastasis by decreasing MAGEB2 expression through FOXO4.","date":"2023","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37002972","citation_count":20,"is_preprint":false},{"pmid":"32149459","id":"PMC_32149459","title":"LncRNA GUARDIN suppresses cellular senescence through a LRP130-PGC1α-FOXO4-p21-dependent signaling axis.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/32149459","citation_count":20,"is_preprint":false},{"pmid":"27911272","id":"PMC_27911272","title":"FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27911272","citation_count":20,"is_preprint":false},{"pmid":"33159395","id":"PMC_33159395","title":"Primary myxoid and epithelioid mesenchymal tumor of the kidney with a novel GLI1-FOXO4 fusion.","date":"2020","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33159395","citation_count":20,"is_preprint":false},{"pmid":"32329448","id":"PMC_32329448","title":"MicroRNA-328-3p Protects Vascular Endothelial Cells Against Oxidized Low-Density Lipoprotein Induced Injury via Targeting Forkhead Box Protein O4 (FOXO4) in Atherosclerosis.","date":"2020","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/32329448","citation_count":20,"is_preprint":false},{"pmid":"22005198","id":"PMC_22005198","title":"FoxO4 inhibits atherosclerosis through its function in bone marrow derived cells.","date":"2011","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/22005198","citation_count":20,"is_preprint":false},{"pmid":"34251583","id":"PMC_34251583","title":"FoxO4 negatively modulates USP10 transcription to aggravate the apoptosis and oxidative stress of hypoxia/reoxygenation-induced cardiomyocytes by regulating the Hippo/YAP pathway.","date":"2021","source":"Journal of bioenergetics and biomembranes","url":"https://pubmed.ncbi.nlm.nih.gov/34251583","citation_count":20,"is_preprint":false},{"pmid":"32228643","id":"PMC_32228643","title":"Upregulation of microRNA-328-3p by hepatitis B virus contributes to THLE-2 cell injury by downregulating FOXO4.","date":"2020","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32228643","citation_count":19,"is_preprint":false},{"pmid":"31333784","id":"PMC_31333784","title":"A medicinal and edible formula YH0618 ameliorates the toxicity induced by Doxorubicin via regulating the expression of Bax/Bcl-2 and FOXO4.","date":"2019","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31333784","citation_count":19,"is_preprint":false},{"pmid":"31602247","id":"PMC_31602247","title":"Tetrahydrocurcumin protects against spinal cord injury and inhibits the oxidative stress response by regulating FOXO4 in model rats.","date":"2019","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31602247","citation_count":19,"is_preprint":false},{"pmid":"34631691","id":"PMC_34631691","title":"FOXO4 Inhibits the Migration and Metastasis of Colorectal Cancer by Regulating the APC2/β-Catenin Axis.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34631691","citation_count":18,"is_preprint":false},{"pmid":"29904119","id":"PMC_29904119","title":"WNK1 regulates skeletal muscle cell hypertrophy by modulating the nuclear localization and transcriptional activity of FOXO4.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29904119","citation_count":18,"is_preprint":false},{"pmid":"24663349","id":"PMC_24663349","title":"FOXO4-knockdown suppresses oxidative stress-induced apoptosis of early pro-angiogenic cells and augments their neovascularization capacities in ischemic limbs.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24663349","citation_count":18,"is_preprint":false},{"pmid":"31866399","id":"PMC_31866399","title":"KLF2 induces the senescence of pancreatic cancer cells by cooperating with FOXO4 to upregulate p21.","date":"2019","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/31866399","citation_count":17,"is_preprint":false},{"pmid":"35913584","id":"PMC_35913584","title":"Extracellular histones induce inflammation and senescence of vascular smooth muscle cells by activating the AMPK/FOXO4 signaling pathway.","date":"2022","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/35913584","citation_count":17,"is_preprint":false},{"pmid":"35481640","id":"PMC_35481640","title":"FOXO4 interacts with p53 TAD and CRD and inhibits its binding to DNA.","date":"2022","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/35481640","citation_count":16,"is_preprint":false},{"pmid":"36106640","id":"PMC_36106640","title":"The FoxO4/DKK3 axis represses IFN-γ expression by Th1 cells and limits antimicrobial immunity.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36106640","citation_count":16,"is_preprint":false},{"pmid":"25437444","id":"PMC_25437444","title":"MSTN, mTOR and FoxO4 are involved in the enhancement of breast muscle growth by methionine in broilers with lower hatching weight.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25437444","citation_count":16,"is_preprint":false},{"pmid":"35196182","id":"PMC_35196182","title":"C1q/tumor necrosis factor-related protein-3 (CTRP3) activated by forkhead box O4 (FOXO4) down-regulation protects retinal pericytes against high glucose-induced oxidative damage through nuclear factor erythroid 2-related factor 2 (Nrf2)/Nuclear factor-kappaB (NF-κB) signaling.","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/35196182","citation_count":16,"is_preprint":false},{"pmid":"27593478","id":"PMC_27593478","title":"Inhibition of skeletal muscle atrophy during torpor in ground squirrels occurs through downregulation of MyoG and inactivation of Foxo4.","date":"2016","source":"Cryobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27593478","citation_count":16,"is_preprint":false},{"pmid":"36700213","id":"PMC_36700213","title":"The role of FOXO4/NFAT2 signaling pathway in dysfunction of human coronary endothelial cells and inflammatory infiltration of vasculitis in Kawasaki disease.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36700213","citation_count":15,"is_preprint":false},{"pmid":"33450250","id":"PMC_33450250","title":"FOXO4 Transactivation Domain Interaction with Forkhead DNA Binding Domain and Effect on Selective DNA Recognition for Transcription Initiation.","date":"2021","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33450250","citation_count":15,"is_preprint":false},{"pmid":"33577016","id":"PMC_33577016","title":"Deacetylation of FOXO4 by Sirt1 stabilizes chondrocyte extracellular matrix upon activating SOX9.","date":"2021","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33577016","citation_count":15,"is_preprint":false},{"pmid":"26797321","id":"PMC_26797321","title":"The DNA damage repair protein Ku70 regulates tumor cell and hepatic carcinogenesis by interacting with FOXO4.","date":"2015","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/26797321","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51894,"output_tokens":11218,"usd":0.161976,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22189,"output_tokens":9026,"usd":0.168297,"stage2_stop_reason":"end_turn"},"total_usd":0.330273,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"NMR solution structure of the DNA-binding domain (forkhead domain) of FOXO4 (AFX) was determined, revealing a three-helix bundle resting on a small antiparallel beta-sheet with two wing-like loops, structurally similar to HNF3-gamma and FREAC-11 despite low sequence identity.\",\n      \"method\": \"High-resolution NMR spectroscopy\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution NMR structure with functional domain context, reported in peer-reviewed journal\",\n      \"pmids\": [\"11352721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Two PKB/Akt phosphorylation sites (Thr-28 and Ser-193) on FOXO4 create binding motifs for 14-3-3 proteins; doubly phosphorylated FOXO4 forms a 1:2 complex with 14-3-3ζ (KD <30 nM), and both phosphorylation sites are required for complete inhibition of FOXO4 binding to its target DNA (insulin response element).\",\n      \"method\": \"In vitro phosphorylation by PKB, analytical gel filtration, sedimentation equilibrium, electrophoretic mobility shift assay\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro binding with quantitative biophysics and mutagenesis, multiple orthogonal methods\",\n      \"pmids\": [\"14690436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CBP acetyltransferase interacts with FOXO4 (AFX/FOXO4) via its CH1 region and acetylates it at lysine residues K186, K189, and K408, resulting in inhibition of FOXO4 transcriptional activity; arginine substitutions at these lysines enhance transcriptional activity.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis (K→R), luciferase reporter assay, TSA treatment\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis with functional reporter assay, single lab, multiple methods\",\n      \"pmids\": [\"12964026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Nuclear FOXO4 expression down-regulates HIF-1α protein levels through a mechanism independent of prolyl hydroxylation and VHL-mediated ubiquitin-proteasome degradation, thereby suppressing hypoxia-responsive genes (VEGF, GLUT1, EPO).\",\n      \"method\": \"Ectopic FOXO4 expression, prolyl hydroxylase inhibition, HIF-1α proline mutants, reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal approaches (mutants, inhibitors, reporters) in single lab\",\n      \"pmids\": [\"12761217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CBP acetyltransferase binds FOXO4 and acetylates it upon oxidative stress (H2O2), inhibiting FOXO4 transcriptional activity; the NAD-dependent deacetylase hSir2(SIRT1) binds and deacetylates FOXO4, counteracting CBP-mediated inhibition and prolonging FOXO-dependent stress gene transcription.\",\n      \"method\": \"Co-immunoprecipitation, acetylation assays, siRNA knockdown, luciferase reporter assay, overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, enzymatic assay, functional reporter, replicated across multiple FOXO family members and independent of earlier CBP study\",\n      \"pmids\": [\"15126506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FOXO4 represses smooth muscle cell (SMC) differentiation by directly interacting with and inhibiting myocardin, a transcriptional coactivator of smooth muscle genes; PI3K/Akt-mediated nuclear export of FOXO4 releases myocardin from inhibition, promoting SMC differentiation. siRNA knockdown of FOXO4 enhances myocardin activity and SMC differentiation.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, reporter assays, dominant-negative and constitutively active constructs, immunofluorescence\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP, siRNA loss-of-function with defined phenotype, reporter assays, multiple orthogonal methods\",\n      \"pmids\": [\"16054032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Phosphorylation of FOXO4 at Thr-32 and Ser-197 (but not Ser-262) by PKB/Akt is required for cytoplasmic retention and transcriptional inactivation; mutations at Thr32 or Ser197 to Ala result in constitutive nuclear localization and 3–5-fold increased transcriptional activity.\",\n      \"method\": \"Site-directed mutagenesis, subcellular fractionation, immunoblotting with phosphosite-specific antibodies, transcriptional reporter assay\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis + fractionation + functional reporter, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"16272144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"14-3-3 protein binding to phosphorylated FOXO4 NLS significantly changes the environment around the NLS and reduces its flexibility, as shown by site-directed AEDANS labeling and fluorescence spectroscopy; phosphorylation alone or DNA binding have only minor effects on NLS structure.\",\n      \"method\": \"Site-directed fluorescent labeling (AEDANS), steady-state and time-resolved fluorescence spectroscopy, in vitro kinase assay\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — fluorescence-based structural analysis with controls, single lab\",\n      \"pmids\": [\"16114898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RANKL signaling through RANK Motif 1 (369PFQEP373) promotes osteoclast survival by activating Akt/PKB, which specifically phosphorylates FOXO4 (AFX) among multiple potential downstream targets, identifying FOXO4 as a key downstream effector of RANK-Akt signaling in osteoclast survival.\",\n      \"method\": \"RANK cytoplasmic motif mutagenesis, immunoblotting for phospho-FOXO4, osteoclast survival assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic domain mutagenesis combined with biochemical phosphorylation readout, single lab\",\n      \"pmids\": [\"16260781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"FOXO4 undergoes monoubiquitination in response to oxidative stress, which promotes its nuclear relocalization and increases transcriptional activity. The deubiquitinase USP7/HAUSP interacts with and deubiquitinates FOXO4 under oxidative stress conditions, negatively regulating FOXO4 transcriptional activity toward endogenous promoters without affecting protein half-life.\",\n      \"method\": \"Co-immunoprecipitation, in vivo ubiquitination assay, siRNA knockdown, subcellular fractionation, reporter assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, multiple orthogonal methods (fractionation, ubiquitination assay, reporter), single lab with rigorous controls\",\n      \"pmids\": [\"16964248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FoxO4 activates transcription of the MMP9 gene in response to TNF-α signaling in vascular smooth muscle cells, requiring both the N-terminal Sp1-interactive domain and the C-terminal transactivation domain of FoxO4; FoxO4 knockdown (siRNA) or knockout reduces SMC migration in vitro and neointimal formation and MMP9 expression in vivo.\",\n      \"method\": \"siRNA knockdown, gene knockout, reporter assays (MMP9 promoter-luciferase), in vitro migration assay, in vivo vascular injury model\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO plus in vitro siRNA with defined mechanistic readouts and domain-mapping\",\n      \"pmids\": [\"17242183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Both the N-terminal loop (upstream of helix H1) and wing W2 of the FOXO4 forkhead domain are required for stable DNA binding; deletion of either region partially reduces DNA binding, while simultaneous deletion of both significantly inhibits it. PKB-mediated phosphorylation of wing W2 significantly inhibits DNA binding only in the absence of the N-terminal loop; 14-3-3 binding efficiently reduces DNA binding regardless of N-terminal loop status.\",\n      \"method\": \"FRET time-resolved fluorescence spectroscopy, molecular dynamics simulations, in vitro DNA binding assays, in vitro PKB phosphorylation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — FRET structural analysis combined with mutagenesis and molecular dynamics, single lab\",\n      \"pmids\": [\"17244620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"AGE/RAGE signaling in podocytes causes Akt dephosphorylation and FOXO4 transcriptional activation, leading to upregulation of the pro-apoptotic protein Bim; siRNA-mediated knockdown of FOXO4 abolishes AGE-BSA-induced podocyte apoptosis.\",\n      \"method\": \"siRNA knockdown, immunoblotting, apoptosis assays (flow cytometry), FOXO4 transcriptional activity readout\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function (siRNA) with defined downstream target (Bim) and apoptosis phenotype, single lab\",\n      \"pmids\": [\"17667983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Mdm2 acts as an E3 ubiquitin ligase for FOXO4, directly co-immunoprecipitating with FOXO4 and inducing its (multi)mono-ubiquitination in vitro and in vivo in an ATP-dependent manner; siRNA-mediated depletion of Mdm2 inhibits H2O2-induced FOXO4 mono-ubiquitination, and Mdm2-mediated ubiquitination regulates FOXO4 transcriptional activity.\",\n      \"method\": \"In vitro ubiquitination assay, co-immunoprecipitation, siRNA knockdown, in vivo ubiquitination assay, reporter assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstituted ubiquitination assay plus Co-IP and in vivo siRNA rescue, multiple orthogonal methods\",\n      \"pmids\": [\"18665269\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TNF-α increases nuclear FOXO4 protein and induces atrogin-1/MAFbx mRNA expression in C2C12 myotubes via a mechanism independent of AKT-Foxo1/3 signaling; two distinct siRNA sequences targeting Foxo4 reduce TNF-induced atrogin mRNA by ~33%.\",\n      \"method\": \"siRNA knockdown, immunoblotting for nuclear FOXO4, qPCR for atrogin mRNA, pharmacological AKT inhibition (wortmannin)\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two independent siRNAs with phenotypic readout, pathway pharmacology controls, single lab\",\n      \"pmids\": [\"18701653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Reactive oxygen species induce formation of cysteine-thiol disulfide-dependent complexes between FoxO4 and p300/CBP acetyltransferase; modulation of FoxO4 biological activity by p300/CBP-mediated acetylation is fully dependent on formation of this redox-dependent complex, directly linking cellular redox state to FoxO4 activity.\",\n      \"method\": \"Biochemical crosslinking, thiol-reactive probes, co-immunoprecipitation, mutagenesis of cysteine residues, transcriptional reporter assays\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (redox crosslinking, Co-IP, cysteine mutagenesis, functional reporters) in single rigorous study\",\n      \"pmids\": [\"19648934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"14-3-3 protein physically contacts and masks the DNA-binding interface of FOXO4 upon binding; six inter-protein FRET distances reveal that the forkhead domain of FOXO4 is docked within the central channel of the 14-3-3 dimer, without causing dramatic conformational change of FOXO4.\",\n      \"method\": \"Time-resolved FRET fluorescence spectroscopy, site-specific AEDANS labeling, tryptophan fluorescence\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — FRET distance measurements with multiple labeled sites, structural model validated by multiple spectroscopic methods\",\n      \"pmids\": [\"19416966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FoxO4 inhibits NF-κB transcriptional activity; Foxo4-null mice show increased NF-κB activity in vivo and increased susceptibility to colonic injury-induced colitis, with upregulation of chemokine CCL5 and increased intestinal permeability due to downregulation of tight junction proteins ZO-1 and claudin-1.\",\n      \"method\": \"Foxo4 genetic knockout, microarray, NF-κB reporter assays, flow cytometry for immune cell infiltration, Western blot for tight junction proteins\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic KO with multiple molecular and cellular mechanistic readouts\",\n      \"pmids\": [\"19560465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"EGF/PI3K/Akt signaling causes phosphorylation of FOXO4 and inhibition of ANXA8 transcription in cholangiocarcinoma cells; FOXO4 phosphorylation downstream of EGFR-PI3K-Akt leads to inhibition of ANXA8 gene transcription, promoting EMT and metastasis.\",\n      \"method\": \"PI3K/Akt inhibitor treatment, FOXO4 overexpression, ANXA8 reporter assays, in vitro invasion assay, in vivo metastasis assay\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with functional phenotypic readouts, single lab\",\n      \"pmids\": [\"19376120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Crystal structure of human FOXO4 DNA-binding domain in complex with 13-bp DNA at 1.9 Å resolution reveals helix H3 docked into the major groove providing all base-specific contacts, while the N-terminus and wing W1 contact phosphate groups; the H2-H3 loop has a different conformation from other FOXO-DBD structures and participates in DNA binding.\",\n      \"method\": \"X-ray crystallography (1.9 Å resolution crystal structure)\",\n      \"journal\": \"Acta crystallographica. Section D, Biological crystallography\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structure with atomic detail of protein-DNA contacts\",\n      \"pmids\": [\"21123876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Ku70 (but not Ku80) is necessary and sufficient for interaction with FOXO4, identified by tandem-affinity purification/mass spectrometry; Ku70 inhibits FOXO4-mediated p27kip1 transcription and cell cycle arrest by >40%, and sequesters FOXO4 in the nucleus. Low levels of oxidative stress (50 µM H2O2) increase the Ku70-FOXO4 interaction stoichiometry while higher levels cause dissociation.\",\n      \"method\": \"Tandem-affinity purification, mass spectrometry, biochemical co-immunoprecipitation, luciferase reporter assay, Ku70 RNAi, immunofluorescence, flow cytometry, Ku70-/- ES cell rescue\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — unbiased proteomics discovery plus multiple orthogonal validation methods (Co-IP, reporter, RNAi, KO rescue, imaging)\",\n      \"pmids\": [\"20570964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PKG activation causes β-catenin to bind FOXO4 in colon cancer cells in a JNK-dependent manner, leading to increased nuclear FOXO4 content and expression of FOXO target genes (MnSOD, catalase); FOXO4-specific siRNA completely blocks PKG-mediated inhibition of TCF transcriptional activity.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, nuclear fractionation, luciferase reporter assays, pharmacological inhibitors\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and siRNA rescue with multiple reporter readouts, single lab\",\n      \"pmids\": [\"20348951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"O-GlcNAcylation of FOXO4 is induced by H2O2 treatment through increased association of FOXO4 with OGT (the O-GlcNAc transferase); O-GlcNAcylation enhances FOXO4 transcriptional activity under acute oxidative stress.\",\n      \"method\": \"Co-immunoprecipitation, O-GlcNAc immunoblotting, transcriptional reporter assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for protein-enzyme interaction plus functional reporter, single lab\",\n      \"pmids\": [\"19932102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Ataxin-3 (ATXN3) interacts with FOXO4 and activates FOXO4-dependent transcription of the SOD2 gene; upon oxidative stress, ATXN3 and FOXO4 co-translocate to the nucleus and co-bind the SOD2 promoter; mutant ATXN3 (as in SCA3) has reduced ability to activate FOXO4-mediated SOD2 expression and interferes with FOXO4 binding to the SOD2 promoter.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), reporter assays, ATXN3 RNAi knockdown, immunofluorescence\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP, ChIP, RNAi loss-of-function and gain-of-function with mechanistic promoter binding readout\",\n      \"pmids\": [\"21536589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"AGE-BSA treatment increases FOXO4 acetylation in podocytes; acetylation of FOXO4 (regulated by SIRT1, which is downregulated by AGE-BSA) is required for FOXO4 binding to the Bcl2l11 (Bim) promoter and transcriptional upregulation of Bim leading to podocyte apoptosis; SIRT1 overexpression prevents AGE-induced podocyte apoptosis.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), FOXO4 acetylation immunoprecipitation, SIRT1 overexpression, siRNA, in vivo db/db mouse model\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP for direct promoter binding, acetylation biochemistry, in vitro and in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"21858169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FoxO4 inactivation downstream of the AMPK-mTORC1-S6K1-IRS-1-Akt2 pathway mediates adiponectin-induced vascular smooth muscle cell differentiation; adiponectin activates AMPKα2, which inhibits mTORC1/S6K1, stabilizing IRS-1 and driving Akt2-mediated FoxO4 phosphorylation and nuclear exclusion to allow contractile gene expression.\",\n      \"method\": \"siRNA knockdown of pathway components, overexpression, pharmacological inhibitors, VSMC differentiation assays\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological epistasis with defined phenotypic readout, single lab\",\n      \"pmids\": [\"21454807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Foxk1 physically interacts with Foxo4 and represses Foxo4 transcriptional activity, thereby promoting muscle progenitor cell proliferation; Foxk1 knockdown causes cell cycle arrest and increased Foxo4 target gene expression, while Foxk1 overexpression retards muscle differentiation.\",\n      \"method\": \"Co-immunoprecipitation, reporter assays, siRNA knockdown, overexpression in C2C12 cells\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus loss/gain-of-function with functional cell cycle readout, single lab\",\n      \"pmids\": [\"22956541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FoxO4 activates Arg1 (arginase 1) transcription by binding to a FoxO-binding site in the Arg1 promoter in endothelial cells; in FoxO4 endothelial-specific knockout mice, post-MI cardiac function is improved and neutrophil accumulation is reduced; FoxO4 acts upstream of Arg1 to suppress nitric oxide and promote neutrophil infiltration.\",\n      \"method\": \"Conditional endothelial/cardiomyocyte-specific knockout mice, luciferase reporter assay with Arg1 promoter, ChIP, siRNA, nitric oxide measurement, cardiac functional analysis (echocardiography)\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific in vivo KO, direct promoter binding (reporter + ChIP), multiple phenotypic readouts\",\n      \"pmids\": [\"26438688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"XBP1 unspliced form (XBP1u) directly associates with the N-terminus of FoxO4 in the cytoplasm, preventing FoxO4 nuclear translocation; blocking the XBP1u-FoxO4 interaction promotes nuclear FoxO4 translocation, represses smooth muscle cell marker genes, and stimulates aortic aneurysm formation in vivo, defining a XBP1u-FoxO4-myocardin axis in VSMC homeostasis.\",\n      \"method\": \"Co-immunoprecipitation, conditional SMC-specific XBP1 knockout mice, in vivo aneurysm models, immunofluorescence for nuclear FoxO4\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct protein interaction by Co-IP plus in vivo genetic model with functional consequence, multiple readouts\",\n      \"pmids\": [\"29089350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"WNK1 kinase positively regulates skeletal muscle cell hypertrophy by modulating FOXO4 nuclear localization; WNK1 silencing increases FOXO4 nuclear accumulation and induces atrogene (MAFbx and MuRF1) transcription and myotube atrophy, which is completely reversed by co-silencing of FOXO4.\",\n      \"method\": \"siRNA knockdown (WNK1, SPAK/OSR1, FOXO4), immunofluorescence for FOXO4 nuclear localization, qPCR for atrogenes, myotube diameter measurement\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis by double siRNA knockdown with defined phenotypic and molecular readouts, single lab\",\n      \"pmids\": [\"29904119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Fhl2 interacts with Foxk1 and, in a dose-dependent fashion, promotes Foxk1-mediated transcriptional repression of Foxo4 activity, contributing to regulation of myogenic progenitor cell activity; Fhl2 knockdown results in cell cycle arrest.\",\n      \"method\": \"Yeast two-hybrid screen, transcriptional reporter assay, siRNA knockdown, immunohistochemistry\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — yeast two-hybrid plus reporter assay and knockdown, single lab\",\n      \"pmids\": [\"20013826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"COP1 E3 ubiquitin ligase directly interacts with FOXO4 through a VP motif on FOXO4 and promotes its ubiquitin-mediated proteasomal degradation in response to EGF signaling; CSN6 enhances COP1 E3 ligase activity toward FOXO4. FOXO4 directly binds and suppresses promoters of serine-glycine-one-carbon (SGOC) pathway genes.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, promoter-reporter and ChIP assays, CSN6 siRNA, metabolomics\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination assay, promoter binding, single lab with multiple methods\",\n      \"pmids\": [\"33101846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The FOXO4 C-terminal disordered transactivation domain (TAD) binds β-catenin through two defined interaction sites, regulated by combined PKB/AKT- and CK1-mediated phosphorylation; β-catenin binding competes with an autoinhibitory intramolecular interaction between the FOXO4 TAD and its own forkhead DNA-binding domain, enhancing FOXO4 transcriptional activity. ICAT (β-catenin inhibitor) can bind β-catenin simultaneously with FOXO4.\",\n      \"method\": \"NMR spectroscopy, biochemical binding assays, phosphorylation mutagenesis, reporter assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR structural analysis combined with mutagenesis and functional reporter assays, multiple orthogonal methods\",\n      \"pmids\": [\"34320339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FOXO4 TAD and the forkhead DNA-binding domain (FHD) form an intramolecular complex via hydrophobic interactions; TAD and DNA share the same FHD surface for binding, and the FHD-TAD complex selectively shows slow exchange with target DNA and fast exchange with non-target DNA, enabling selective target sequence recognition.\",\n      \"method\": \"Solution NMR spectroscopy, DNA binding assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — atomic-resolution NMR of intramolecular complex with functional DNA-binding kinetics, single lab\",\n      \"pmids\": [\"33450250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FOXO4 directly binds the LDHA (lactate dehydrogenase A) promoter and inactivates its transcriptional activity in a dose-dependent manner; FOXO4 expression is itself transcriptionally repressed by HIF-1α under hypoxia, placing FOXO4 downstream of HIF-1α in the regulation of glycolysis.\",\n      \"method\": \"ChIP, promoter-reporter luciferase assay, FOXO4 overexpression/silencing, metabolic flux assays\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay for direct promoter binding, overexpression/KD with functional metabolic readout, single lab\",\n      \"pmids\": [\"33463054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Fasting in humans activates FOXO4 in CD4+ T cells, and FOXO4 transcriptionally upregulates FKBP5 (FK506-binding protein 5); genetic gain- or loss-of-function of FOXO4 and FKBP5 modulates TH1 and TH17 cytokine production; FOXO4/FKBP5 axis downregulates mTORC1 signaling and suppresses STAT1/3 activation.\",\n      \"method\": \"RNA sequencing, flow cytometry, gain-of-function and loss-of-function genetic approaches, FOXO4 ChIP analysis (bioinformatics), cytokine measurement\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic gain/loss-of-function with defined cytokine phenotype, transcriptomic target identification, human subject data\",\n      \"pmids\": [\"33723462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FOXO4 negatively regulates transcription of USP10; FoxO4 overexpression reduces USP10 levels and blocks Hippo/YAP signaling, aggravating apoptosis and oxidative stress in hypoxia/reoxygenation-treated cardiomyocytes.\",\n      \"method\": \"Dual luciferase reporter assay, ChIP, siRNA/overexpression, western blot for YAP pathway proteins, TUNEL and ROS assays\",\n      \"journal\": \"Journal of bioenergetics and biomembranes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay for direct promoter binding with functional phenotypic readout, single lab\",\n      \"pmids\": [\"34251583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FOXO4 directly binds the ENPP2 promoter (transcription factor binding validated by dual-luciferase and ChIP assays) and inhibits ENPP2 expression; FoxO4 overexpression partially reverses ENPP2-mediated protection of cardiomyocytes against doxorubicin-induced ferroptosis.\",\n      \"method\": \"Dual-luciferase reporter assay, ChIP, overexpression, ferroptosis/oxidative stress assays\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter for direct promoter binding with functional rescue readout, single lab\",\n      \"pmids\": [\"34296293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FOXO4 transcriptionally activates SOX9 by binding to its promoter (validated by ChIP and dual-luciferase reporter assay); Sirt1-mediated deacetylation of FOXO4 promotes SOX9 expression and stabilizes chondrocyte ECM. FOXO4 acetylation is increased by IL-1β, and FOXO4 knockdown abolishes Sirt1-induced SOX9 expression.\",\n      \"method\": \"ChIP, dual-luciferase reporter assay, FOXO4 siRNA knockdown, Sirt1 overexpression, Western blot for FOXO4 acetylation\",\n      \"journal\": \"European review for medical and pharmacological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay for promoter binding with siRNA epistasis, single lab\",\n      \"pmids\": [\"33577016\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOXO4 interacts with both the transactivation domain (TAD) and cysteine-rich domain (CRD) of p53, as determined by NMR, chemical cross-linking, and analytical ultracentrifugation; p53 TAD interaction with the FOXO4 forkhead domain is essential for overall complex stability; complex formation blocks p53 binding to DNA but does not affect FOXO4's own DNA-binding properties.\",\n      \"method\": \"NMR spectroscopy, chemical cross-linking, analytical ultracentrifugation, in vitro DNA binding assays\",\n      \"journal\": \"Protein science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple biophysical methods (NMR, AUC, crosslinking) with functional DNA binding assays in single rigorous study\",\n      \"pmids\": [\"35481640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FoxO4 transcriptionally represses NFAT2 by binding to the NFAT2 promoter in human coronary artery endothelial cells (validated by ChIP and luciferase assay); Foxo4 knockout increases vasculitis in a mouse KD model, and NFAT2 inhibition reverses this effect, defining a FOXO4/NFAT2 axis in vascular inflammation.\",\n      \"method\": \"ChIP, luciferase reporter assay, Foxo4 knockout mice, NFAT2 overexpression/knockdown, in vivo KD vasculitis model\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter with in vivo KO epistasis, single lab\",\n      \"pmids\": [\"36700213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FoxO4 directly binds and transcriptionally represses the Dkk3 (Dickkopf-3) gene (identified by genome-wide occupancy/ChIP-seq and transcriptomics); DKK3 mediates FoxO4's suppression of IFN-γ production in Th1 cells by downregulating LEF1 expression; conditional FoxO4 deletion in CD4+ T cells enhances Th1 responses to bacterial infection.\",\n      \"method\": \"ChIP-seq (genome-wide occupancy), RNA-seq, conditional T cell-specific KO mice, recombinant DKK3 protein reconstitution, cytokine measurement\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq plus in vivo conditional KO with protein reconstitution epistasis, multiple orthogonal methods\",\n      \"pmids\": [\"36106640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOXO4 binds the CTRP3 promoter and inhibits CTRP3 transcription (validated by JASPAR prediction, ChIP, and luciferase reporter assay); FOXO4 upregulation in high-glucose conditions suppresses CTRP3 expression, modulating the Nrf2/NF-κB pathway in retinal pericytes.\",\n      \"method\": \"ChIP, dual-luciferase reporter assay, FOXO4 overexpression, bioinformatics (JASPAR)\",\n      \"journal\": \"Bioengineered\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter for direct promoter binding with functional overexpression readout, single lab\",\n      \"pmids\": [\"35196182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"KLF2 physically interacts with FOXO4 and cooperates with FOXO4 to induce transcription of p21, driving senescence of pancreatic cancer cells; knockdown of p21 or FOXO4 impairs KLF2-induced senescence.\",\n      \"method\": \"Co-immunoprecipitation, reporter assays, siRNA knockdown, senescence assays (SA-β-gal)\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, siRNA epistasis with defined senescence phenotype, single lab\",\n      \"pmids\": [\"31866399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TET1 transcriptionally activates FOXO4 expression; FOXO4 directly interacts with β-catenin and sequesters it in the cytoplasm, inhibiting β-catenin-mediated transcription of Wnt target genes (including EpCAM); FOXO4 modulation reverses TET1 effects on EMT and cancer stem cell self-renewal.\",\n      \"method\": \"Co-immunoprecipitation, RNA-seq, overexpression and knockdown, β-catenin localization assay, reporter assays, liver metastasis in vivo model\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for direct interaction, RNA-seq target identification, in vivo rescue experiments, single lab\",\n      \"pmids\": [\"35805009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FOXO4 binds the APC2 promoter and transcriptionally upregulates APC2 expression, leading to increased phosphorylated degradation of β-catenin and suppression of stemness genes; FOXO4 overexpression inhibits CRC cell migration and metastasis, which is reversed by APC2 knockdown.\",\n      \"method\": \"ChIP, overexpression, siRNA knockdown (APC2), in vivo metastasis assay, immunohistochemistry\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for direct promoter binding with siRNA epistasis and in vivo validation, single lab\",\n      \"pmids\": [\"34631691\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FOXO4 is a forkhead transcription factor whose activity, subcellular localization, and protein interactions are regulated by multiple post-translational modifications—including PKB/Akt-mediated phosphorylation at Thr-28/Ser-197 (promoting 14-3-3 binding and cytoplasmic retention), CBP/p300-mediated acetylation (via redox-dependent disulfide complex formation, inhibiting activity), SIRT1-mediated deacetylation (restoring activity), Mdm2/COP1-mediated (poly)monoubiquitination (modulating nuclear localization and transcriptional activity), USP7/HAUSP-mediated deubiquitination, and O-GlcNAcylation (enhancing activity under stress)—and through direct protein-protein interactions with partners including 14-3-3, myocardin, β-catenin, p53, Ku70, Mdm2, ataxin-3, Foxk1, XBP1u, KLF2, and DKK3; FOXO4 directly binds promoters of target genes including p27, MMP9, Arg1, LDHA, SOD2, Bim, NFAT2, DKK3, APC2, ENPP2, USP10, SOX9, and CTRP3 to regulate cell cycle, apoptosis, differentiation, inflammation, oxidative stress response, glycolysis, and senescence.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FOXO4 is a forkhead transcription factor that integrates growth-factor and redox signaling to control cell cycle arrest, apoptosis, oxidative-stress responses, differentiation, and inflammation through a forkhead DNA-binding domain that docks helix H3 into the DNA major groove [#0, #19]. Its activity is gated chiefly by PI3K/Akt: phosphorylation at Thr-28/Thr-32 and Ser-193/Ser-197 creates 14-3-3 binding motifs, and the 14-3-3 dimer masks the DNA-binding interface to drive cytoplasmic retention and transcriptional inactivation, whereas phosphosite mutants are constitutively nuclear and hyperactive [#1, #6, #16]. A second regulatory layer is redox-coupled and reversible: oxidative stress promotes cysteine-disulfide complex formation with CBP/p300, which acetylates FOXO4 to inhibit it, while SIRT1 deacetylates FOXO4 to restore stress-gene transcription, and concurrent monoubiquitination (by Mdm2) and O-GlcNAcylation (via OGT) drive FOXO4 into the nucleus and enhance activity, with USP7/HAUSP reversing the ubiquitin signal and COP1 instead targeting FOXO4 for proteasomal degradation [#4, #9, #13, #15, #22, #31]. FOXO4 transcriptional output is further tuned by an autoinhibitory intramolecular contact between its disordered C-terminal transactivation domain and the forkhead domain, which \\u03b2-catenin binding relieves to boost activity and enable selective target recognition [#32, #33]. Through these mechanisms FOXO4 directly binds and activates targets including p27/p21, Bim, SOD2, and Arg1, and represses targets including LDHA, NFAT2, DKK3, and USP10 to enforce cell-cycle arrest, senescence, apoptosis, glycolytic control, and immune/vascular responses [#20, #23, #24, #27, #34, #36, #40, #41, #43]. A prominent role is the repression of smooth muscle differentiation by direct binding and inhibition of the coactivator myocardin, an axis itself controlled by cytoplasmic sequestration via XBP1u [#5, #28].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established the structural basis for FOXO4 DNA recognition by defining its forkhead domain fold, the prerequisite for interpreting how modifications and partners control DNA binding.\",\n      \"evidence\": \"High-resolution NMR solution structure of the FOXO4 forkhead domain\",\n      \"pmids\": [\"11352721\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No DNA complex in this structure\", \"Does not address full-length protein or regulatory regions\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined how Akt signaling inactivates FOXO4 by showing that dual PKB phosphorylation builds 14-3-3 binding sites that block DNA binding, establishing the core off-switch.\",\n      \"evidence\": \"In vitro PKB phosphorylation, biophysical 14-3-3 binding (gel filtration, sedimentation), EMSA, mutagenesis\",\n      \"pmids\": [\"14690436\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of cytoplasmic retention not yet resolved here\", \"Performed in vitro with isolated domains\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified acetylation as an inhibitory modification by mapping CBP-acetylated lysines whose mutation enhances activity, opening the acetylation arm of FOXO4 regulation.\",\n      \"evidence\": \"Co-IP, K\\u2192R mutagenesis, luciferase reporter, TSA treatment\",\n      \"pmids\": [\"12964026\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab reporter-based readout\", \"Physiological context of acetylation not addressed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Connected acetylation to redox state and showed it is reversible, establishing CBP/SIRT1 as an antagonistic acetylation-deacetylation switch that tunes FOXO4 stress-gene output.\",\n      \"evidence\": \"Co-IP, acetylation/deacetylation assays, siRNA, reporter assays under H2O2\",\n      \"pmids\": [\"15126506\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct deacetylated lysines not exhaustively mapped\", \"Quantitative contribution to endogenous targets unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Refined the phosphorylation code by demonstrating that Thr-32/Ser-197 phosphorylation specifically governs nuclear exclusion and activity, distinguishing functional from non-functional sites.\",\n      \"evidence\": \"Site-directed mutagenesis, subcellular fractionation, phosphosite antibodies, reporter assay\",\n      \"pmids\": [\"16272144\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ser-262 role left undefined\", \"Kinetics of nuclear export not measured\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Revealed a differentiation-control mechanism in which FOXO4 directly inhibits myocardin to repress smooth muscle gene programs, linking Akt-FOXO4 to vascular cell fate.\",\n      \"evidence\": \"Co-IP, siRNA, reporter assays, dominant-negative/CA constructs, immunofluorescence\",\n      \"pmids\": [\"16054032\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interaction interface on myocardin not mapped\", \"In vivo requirement not tested in this study\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Provided spectroscopic evidence that 14-3-3 binding rigidifies the FOXO4 NLS, mechanistically explaining how phosphorylation-dependent 14-3-3 docking enforces cytoplasmic localization.\",\n      \"evidence\": \"Site-directed AEDANS labeling, fluorescence spectroscopy, in vitro kinase assay\",\n      \"pmids\": [\"16114898\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural inference rather than atomic model\", \"Single lab\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established a ubiquitin arm of FOXO4 control by showing oxidative-stress monoubiquitination promotes nuclear localization and that USP7 reverses it, decoupling this regulation from protein turnover.\",\n      \"evidence\": \"Co-IP, in vivo ubiquitination assay, siRNA, fractionation, reporter assays\",\n      \"pmids\": [\"16964248\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitinated lysines not mapped here\", \"E3 ligase not identified in this study\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Dissected the DNA-binding contributions of the N-terminal loop and wing W2 and showed how PKB phosphorylation and 14-3-3 differentially inhibit DNA binding, refining the structural off-switch.\",\n      \"evidence\": \"FRET spectroscopy, molecular dynamics, in vitro DNA binding, PKB phosphorylation\",\n      \"pmids\": [\"17244620\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro fragment system\", \"Endogenous relevance of loop deletions untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated FOXO4 functions as a transcriptional activator in a disease context by driving MMP9 in vascular smooth muscle, with in vivo loss-of-function reducing neointima.\",\n      \"evidence\": \"siRNA, knockout, MMP9 promoter reporter, migration assay, in vivo vascular injury\",\n      \"pmids\": [\"17242183\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sp1 cooperation mechanism not fully resolved\", \"Direct promoter occupancy details limited\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified Mdm2 as the E3 ligase mediating oxidative-stress monoubiquitination of FOXO4, supplying the enzyme acting opposite USP7.\",\n      \"evidence\": \"In vitro and in vivo ubiquitination, Co-IP, siMdm2, reporter assay\",\n      \"pmids\": [\"18665269\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Lysine acceptor sites not mapped\", \"Relationship to COP1-mediated degradation not addressed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Provided the molecular link between cellular redox state and acetylation by showing ROS-induced FOXO4\\u2013p300/CBP disulfide complexes are required for acetylation-dependent regulation.\",\n      \"evidence\": \"Redox crosslinking, thiol probes, Co-IP, cysteine mutagenesis, reporters\",\n      \"pmids\": [\"19648934\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific cysteine pairing in vivo not fully defined\", \"Quantitative redox thresholds unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Resolved how 14-3-3 inhibits FOXO4 at the structural level, docking the forkhead domain into the 14-3-3 central channel to mask the DNA interface without gross conformational change.\",\n      \"evidence\": \"Time-resolved FRET, AEDANS labeling, tryptophan fluorescence\",\n      \"pmids\": [\"19416966\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Distance-based model rather than crystal structure\", \"Full-length protein behavior inferred\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Established FOXO4 as an in vivo suppressor of inflammation by showing Foxo4-null mice have elevated NF-\\u03baB activity and increased colitis susceptibility.\",\n      \"evidence\": \"Foxo4 knockout, microarray, NF-\\u03baB reporter, flow cytometry, Western blot\",\n      \"pmids\": [\"19560465\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect NF-\\u03baB inhibition not separated\", \"Tissue-specific contributions not isolated\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Captured atomic-resolution FOXO4\\u2013DNA contacts, defining the base-specific recognition by helix H3 and phosphate contacts by the N-terminus and wing W1.\",\n      \"evidence\": \"1.9 \\u00c5 X-ray crystal structure of FOXO4 DBD\\u2013DNA complex\",\n      \"pmids\": [\"21123876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isolated DBD only\", \"Does not model regulatory modifications or partners\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified Ku70 as a direct nuclear partner that sequesters FOXO4 and inhibits its p27-driven cell-cycle arrest, adding a redox-tunable protein-interaction control.\",\n      \"evidence\": \"TAP-MS, Co-IP, reporter, RNAi, Ku70-/- rescue, imaging, flow cytometry\",\n      \"pmids\": [\"20570964\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interaction interface not mapped\", \"Generality across cell types untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Linked FOXO4 to Wnt/\\u03b2-catenin signaling by showing PKG-induced \\u03b2-catenin\\u2013FOXO4 binding redirects \\u03b2-catenin to FOXO targets and away from TCF.\",\n      \"evidence\": \"Co-IP, siRNA, fractionation, reporters, pharmacological inhibitors\",\n      \"pmids\": [\"20348951\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding interface defined only later\", \"JNK dependence mechanism unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed O-GlcNAcylation provides a stress-responsive activating modification, with OGT association enhancing FOXO4 activity under acute oxidative stress.\",\n      \"evidence\": \"Co-IP, O-GlcNAc immunoblotting, reporter assay\",\n      \"pmids\": [\"19932102\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Modified residues not mapped\", \"Interplay with phosphorylation/acetylation not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified ataxin-3 as a coactivator that directs FOXO4 to the SOD2 promoter under oxidative stress, with disease-mutant ATXN3 impairing this protective program.\",\n      \"evidence\": \"Co-IP, ChIP, reporters, ATXN3 RNAi, immunofluorescence\",\n      \"pmids\": [\"21536589\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs scaffold role of ATXN3 unresolved\", \"Other FOXO4 targets affected not surveyed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated acetylation-dependent promoter selection by showing FOXO4 acetylation is required for Bim promoter binding, linking the SIRT1/CBP switch to apoptotic output in podocytes.\",\n      \"evidence\": \"ChIP, acetylation IP, SIRT1 overexpression, siRNA, db/db mouse model\",\n      \"pmids\": [\"21858169\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acetyl-lysines driving promoter binding not pinpointed\", \"Disease specificity of mechanism untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Added Foxk1 as a repressive interactor controlling FOXO4 activity to balance progenitor proliferation versus differentiation.\",\n      \"evidence\": \"Co-IP, reporters, siRNA, overexpression in C2C12\",\n      \"pmids\": [\"22956541\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interaction surface not mapped\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed XBP1u as a cytoplasmic anchor of FOXO4 in the XBP1u\\u2013FOXO4\\u2013myocardin axis governing smooth muscle homeostasis and aneurysm protection.\",\n      \"evidence\": \"Co-IP, SMC-specific XBP1 KO mice, aneurysm models, immunofluorescence\",\n      \"pmids\": [\"29089350\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"XBP1u binding determinants not atomically defined\", \"Relationship to Akt/14-3-3 retention not integrated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Implicated WNK1 kinase as an upstream regulator of FOXO4 nuclear localization controlling atrogene-driven muscle atrophy, with FOXO4 silencing fully rescuing the phenotype.\",\n      \"evidence\": \"siRNA (WNK1, SPAK/OSR1, FOXO4), immunofluorescence, qPCR, myotube measurement\",\n      \"pmids\": [\"29904119\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether WNK1 acts directly on FOXO4 unproven\", \"Phosphosite link not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed FOXO4 cooperates with KLF2 to induce p21 and drive senescence, defining a partner-dependent senescence program.\",\n      \"evidence\": \"Co-IP, reporters, siRNA, SA-\\u03b2-gal senescence assays\",\n      \"pmids\": [\"31866399\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct co-occupancy of p21 promoter not shown\", \"Single cancer model\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended the Foxk1 repression axis by identifying Fhl2 as a cofactor enhancing Foxk1-mediated repression of FOXO4 activity in myogenic progenitors.\",\n      \"evidence\": \"Yeast two-hybrid, reporter assay, siRNA, immunohistochemistry\",\n      \"pmids\": [\"20013826\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Y2H interaction not reciprocally validated in cells for FOXO4\", \"Indirect effect on FOXO4\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified COP1 as an E3 ligase that degrades FOXO4 via a VP motif under EGF signaling, distinguishing a proteolytic ubiquitin pathway from the non-degradative Mdm2 route.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, ChIP/reporter, CSN6 siRNA, metabolomics\",\n      \"pmids\": [\"33101846\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interplay with USP7/Mdm2 signaling not reconciled\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated tumor-suppressive transcriptional output by showing FOXO4 activates APC2 to promote \\u03b2-catenin degradation and suppress colorectal metastasis.\",\n      \"evidence\": \"ChIP, overexpression, APC2 siRNA, in vivo metastasis, IHC\",\n      \"pmids\": [\"34631691\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct promoter element not finely mapped\", \"Single tumor type\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Resolved the molecular basis of \\u03b2-catenin\\u2013FOXO4 regulation, showing \\u03b2-catenin binds the disordered TAD and relieves an autoinhibitory TAD\\u2013forkhead contact to enhance activity.\",\n      \"evidence\": \"NMR, biochemical binding, phosphomutagenesis, reporters\",\n      \"pmids\": [\"34320339\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular stoichiometry of competition unknown\", \"Phospho-regulation kinetics in vivo untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined the autoinhibitory intramolecular TAD\\u2013FHD complex as a mechanism for selective target-DNA recognition through differential exchange kinetics.\",\n      \"evidence\": \"Solution NMR, DNA binding assays\",\n      \"pmids\": [\"33450250\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In-cell occurrence of the intramolecular state not directly observed\", \"Effect of modifications on the equilibrium not fully mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed FOXO4 in glycolytic control downstream of HIF-1\\u03b1, showing it directly represses LDHA while being itself repressed by HIF-1\\u03b1 under hypoxia.\",\n      \"evidence\": \"ChIP, reporter, overexpression/silencing, metabolic flux\",\n      \"pmids\": [\"33463054\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cancer context\", \"Quantitative contribution to flux modest\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Expanded FOXO4 repressive targets in cardiac stress by showing it suppresses USP10 and ENPP2 to modulate Hippo/YAP signaling, apoptosis, and ferroptosis.\",\n      \"evidence\": \"ChIP, dual-luciferase, siRNA/overexpression, TUNEL/ROS/ferroptosis assays\",\n      \"pmids\": [\"34251583\", \"34296293\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab reporter-based mechanisms\", \"Direct vs indirect ferroptosis effects unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked FOXO4 to SIRT1-dependent chondrocyte maintenance, showing deacetylated FOXO4 activates SOX9 to stabilize ECM.\",\n      \"evidence\": \"ChIP, dual-luciferase, FOXO4 siRNA, Sirt1 overexpression, acetylation Western\",\n      \"pmids\": [\"33577016\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Acetyl-residues controlling SOX9 binding not mapped\", \"Single tissue model\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established a metabolic-immune role in which fasting-activated FOXO4 upregulates FKBP5 to dampen mTORC1/STAT signaling and modulate TH1/TH17 cytokines.\",\n      \"evidence\": \"RNA-seq, flow cytometry, FOXO4/FKBP5 gain/loss, ChIP bioinformatics, human data\",\n      \"pmids\": [\"33723462\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct FKBP5 promoter binding only bioinformatically inferred\", \"Human genetics correlative\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined how FOXO4 inhibits p53 by binding its TAD and CRD to block p53\\u2013DNA binding while leaving FOXO4's own DNA binding intact, revealing reciprocal transcription-factor cross-inhibition.\",\n      \"evidence\": \"NMR, chemical crosslinking, analytical ultracentrifugation, in vitro DNA binding\",\n      \"pmids\": [\"35481640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular consequences of p53 inhibition not assayed here\", \"Regulation of the interaction unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated FOXO4's vascular-immune role by repressing NFAT2 to restrain vasculitis, validated by in vivo KO epistasis.\",\n      \"evidence\": \"ChIP, luciferase, Foxo4 KO mice, NFAT2 manipulation, KD vasculitis model\",\n      \"pmids\": [\"36700213\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Promoter element not finely resolved\", \"Single disease model\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided genome-wide FOXO4 occupancy showing direct repression of Dkk3 to limit Th1 IFN-\\u03b3 responses, integrating FOXO4 into T-cell immunity.\",\n      \"evidence\": \"ChIP-seq, RNA-seq, T-cell-specific conditional KO, DKK3 reconstitution, cytokines\",\n      \"pmids\": [\"36106640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full target landscape not analyzed beyond DKK3\", \"Upstream activating signal in T cells not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed FOXO4 represses CTRP3 under hyperglycemia, modulating Nrf2/NF-\\u03baB signaling in retinal pericytes.\",\n      \"evidence\": \"ChIP, dual-luciferase, FOXO4 overexpression, JASPAR prediction\",\n      \"pmids\": [\"35196182\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell type\", \"Functional consequence largely correlative\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple, partly antagonistic modification arms (phosphorylation/14-3-3, acetylation, mono- vs degradative ubiquitination, O-GlcNAcylation) and the autoinhibitory TAD\\u2013FHD equilibrium are integrated to set FOXO4 target selectivity and activate or repress specific genes in a given cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified quantitative model of modification cross-talk\", \"Determinants of activator vs repressor mode at individual promoters unknown\", \"In-cell relevance of the intramolecular autoinhibited state not directly demonstrated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [5, 10, 17, 23, 27, 34, 40, 41, 45]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 19, 33]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 39]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 9, 14, 20, 29]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 6, 16, 28, 44]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 6, 8, 16, 21, 25]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 10, 23, 27, 41]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [4, 9, 15, 22, 23]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [17, 35, 40, 41]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [20, 43]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"YWHAZ\", \"CREBBP\", \"SIRT1\", \"MDM2\", \"USP7\", \"CTNNB1\", \"TP53\", \"XRCC6\", \"ATXN3\", \"XBP1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}